JP2016536333A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536333A5 JP2016536333A5 JP2016540311A JP2016540311A JP2016536333A5 JP 2016536333 A5 JP2016536333 A5 JP 2016536333A5 JP 2016540311 A JP2016540311 A JP 2016540311A JP 2016540311 A JP2016540311 A JP 2016540311A JP 2016536333 A5 JP2016536333 A5 JP 2016536333A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- methoxy
- phenylphenyl
- phenyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydroxy cyclopentyl Chemical group 0.000 claims 54
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 150000001412 amines Chemical class 0.000 claims 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 4
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- PRHPXJYSSYNNAX-UHFFFAOYSA-N CC1=C(C=CC=C1COC=1C=C2CCN(CC2=CC=1)CC(=O)O)C1=CC=CC=C1 Chemical compound CC1=C(C=CC=C1COC=1C=C2CCN(CC2=CC=1)CC(=O)O)C1=CC=CC=C1 PRHPXJYSSYNNAX-UHFFFAOYSA-N 0.000 claims 3
- PUGUDYHVJKDRHT-QGZVFWFLSA-N COc1cc(F)cc(c1)-c1cccc(COc2cc(OC)c(CN[C@H](C)C(O)=O)c(OC)c2)c1C Chemical compound COc1cc(F)cc(c1)-c1cccc(COc2cc(OC)c(CN[C@H](C)C(O)=O)c(OC)c2)c1C PUGUDYHVJKDRHT-QGZVFWFLSA-N 0.000 claims 3
- RUJGJXQLELAMPZ-UHFFFAOYSA-N Cc1cc(CN2CCC2)ccc1OCc1cccc(c1C)-c1ccccc1 Chemical compound Cc1cc(CN2CCC2)ccc1OCc1cccc(c1C)-c1ccccc1 RUJGJXQLELAMPZ-UHFFFAOYSA-N 0.000 claims 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 235000019260 propionic acid Nutrition 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- LFDAMPXTOMYVDL-ZWAGFTRDSA-N (1R)-2-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]cyclohexane-1-carboxylic acid Chemical compound COC1=CC(OCC2=C(C)C(=CC=C2)C2=CC=CC=C2)=CC(OC)=C1CC1CCCC[C@H]1C(O)=O LFDAMPXTOMYVDL-ZWAGFTRDSA-N 0.000 claims 2
- VVAYTZXEIIASOX-SANMLTNESA-N (2S)-1-[[2-methoxy-3-methyl-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]piperidine-2-carboxylic acid Chemical compound COc1c(CN2CCCC[C@H]2C(O)=O)ccc(OCc2cccc(c2C)-c2ccccc2)c1C VVAYTZXEIIASOX-SANMLTNESA-N 0.000 claims 2
- RJPOZTIAWSYFDH-RDGATRHJSA-N (2S,4R)-1-[[3-chloro-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]-4-methoxypyrrolidine-2-carboxylic acid Chemical compound CO[C@@H]1C[C@H](N(Cc2ccc(OCc3cccc(c3C)-c3ccccc3)c(Cl)c2)C1)C(O)=O RJPOZTIAWSYFDH-RDGATRHJSA-N 0.000 claims 2
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 claims 2
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 claims 2
- ZHJPFAIDYVOVEG-UHFFFAOYSA-N 1-[3-[[3-methyl-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]propyl]pyrrolidin-2-one Chemical compound CC=1C=C(C=CC=1OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)CNCCCN1C(CCC1)=O ZHJPFAIDYVOVEG-UHFFFAOYSA-N 0.000 claims 2
- XPASSMHSTYAUCI-UHFFFAOYSA-N 4-[[3-methyl-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]butan-2-one Chemical compound CC(=O)CCNCC1=CC=C(OCC2=C(C)C(=CC=C2)C2=CC=CC=C2)C(C)=C1 XPASSMHSTYAUCI-UHFFFAOYSA-N 0.000 claims 2
- QVXDKKPKMDXRDR-UHFFFAOYSA-N C(C)(=O)NCCNC(C)C1=CC(=C(C=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)Cl Chemical compound C(C)(=O)NCCNC(C)C1=CC(=C(C=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)Cl QVXDKKPKMDXRDR-UHFFFAOYSA-N 0.000 claims 2
- VRIBDHIYQYBONN-UHFFFAOYSA-N CC(=O)NCCNCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(Br)c1 Chemical compound CC(=O)NCCNCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(Br)c1 VRIBDHIYQYBONN-UHFFFAOYSA-N 0.000 claims 2
- QLENBQSZSCUQNF-UHFFFAOYSA-N CC(=O)NCCNCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(F)c1 Chemical compound CC(=O)NCCNCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(F)c1 QLENBQSZSCUQNF-UHFFFAOYSA-N 0.000 claims 2
- UTWMGLWCXLEDIM-VPUSJEBWSA-N CC(=O)O[C@@H]1C[C@H](N(Cc2ccc(OCc3cccc(c3C)-c3ccccc3)c(C)c2)C1)C(O)=O Chemical compound CC(=O)O[C@@H]1C[C@H](N(Cc2ccc(OCc3cccc(c3C)-c3ccccc3)c(C)c2)C1)C(O)=O UTWMGLWCXLEDIM-VPUSJEBWSA-N 0.000 claims 2
- LTYRRNPMUQCLPK-UHFFFAOYSA-N CC(CC(O)=O)NCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(C)c1 Chemical compound CC(CC(O)=O)NCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(C)c1 LTYRRNPMUQCLPK-UHFFFAOYSA-N 0.000 claims 2
- DITGSNOUXGPVNN-UHFFFAOYSA-N CC1=C(C=CC=C1C1=CC=CC=C1)COC1=CC=C(C=C1)CN1C(CCCC1)C(=O)O Chemical compound CC1=C(C=CC=C1C1=CC=CC=C1)COC1=CC=C(C=C1)CN1C(CCCC1)C(=O)O DITGSNOUXGPVNN-UHFFFAOYSA-N 0.000 claims 2
- RSILUGRGGAUUNL-UHFFFAOYSA-N CC=1C=C(C=CC=1OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)CN1CC(=CCC1)C(=O)O Chemical compound CC=1C=C(C=CC=1OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)CN1CC(=CCC1)C(=O)O RSILUGRGGAUUNL-UHFFFAOYSA-N 0.000 claims 2
- MPWXPHXWSZZJSZ-UHFFFAOYSA-N CCN1CCCC(C1)NCc1c(OC)cc(OCc2cccc(c2C)-c2ccccc2)cc1OC Chemical compound CCN1CCCC(C1)NCc1c(OC)cc(OCc2cccc(c2C)-c2ccccc2)cc1OC MPWXPHXWSZZJSZ-UHFFFAOYSA-N 0.000 claims 2
- NGWARGISBMFXGR-UHFFFAOYSA-N CN(CC(O)=O)Cc1ccc(OCc2cccc(c2C)-c2ccccc2)c(C)c1 Chemical compound CN(CC(O)=O)Cc1ccc(OCc2cccc(c2C)-c2ccccc2)c(C)c1 NGWARGISBMFXGR-UHFFFAOYSA-N 0.000 claims 2
- UQQACMJMIXWAQX-UHFFFAOYSA-N CN(CC(O)=O)Cc1cccc(OCc2cccc(c2C)-c2ccccc2)c1 Chemical compound CN(CC(O)=O)Cc1cccc(OCc2cccc(c2C)-c2ccccc2)c1 UQQACMJMIXWAQX-UHFFFAOYSA-N 0.000 claims 2
- GIYKJGPKVFLPMA-RSXGOPAZSA-N CO[C@@H]1C[C@H](N(Cc2ccc(OCc3cccc(c3C)-c3ccccc3)c(C)c2)C1)C(O)=O Chemical compound CO[C@@H]1C[C@H](N(Cc2ccc(OCc3cccc(c3C)-c3ccccc3)c(C)c2)C1)C(O)=O GIYKJGPKVFLPMA-RSXGOPAZSA-N 0.000 claims 2
- MVXPOSMNRSCJMP-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN(C)CC(O)=O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN(C)CC(O)=O MVXPOSMNRSCJMP-UHFFFAOYSA-N 0.000 claims 2
- ZBOYJODMIAUJHH-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCCC1C(O)=O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCCC1C(O)=O ZBOYJODMIAUJHH-UHFFFAOYSA-N 0.000 claims 2
- YCCDVBIIHLIURK-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC(C)(C)CN1CCN(C)CC1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC(C)(C)CN1CCN(C)CC1 YCCDVBIIHLIURK-UHFFFAOYSA-N 0.000 claims 2
- DJTHSGNSQOGZGD-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC(C)CC(O)=O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC(C)CC(O)=O DJTHSGNSQOGZGD-UHFFFAOYSA-N 0.000 claims 2
- XYLDJCADECMWKP-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC1CCC1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC1CCC1 XYLDJCADECMWKP-UHFFFAOYSA-N 0.000 claims 2
- YOSNCHLACPIBHY-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC1CCCN(C)C1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC1CCCN(C)C1 YOSNCHLACPIBHY-UHFFFAOYSA-N 0.000 claims 2
- DRFLXZNAAKEZGT-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC(=O)N(C)C Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC(=O)N(C)C DRFLXZNAAKEZGT-UHFFFAOYSA-N 0.000 claims 2
- MFEHNRXGUMAKJB-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCN1CCCC1=O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCN1CCCC1=O MFEHNRXGUMAKJB-UHFFFAOYSA-N 0.000 claims 2
- YZASPJDRTJDVGZ-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCN1CCCCC1=O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCN1CCCCC1=O YZASPJDRTJDVGZ-UHFFFAOYSA-N 0.000 claims 2
- MDRNRIAYLGGFKE-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCN1CCNC(=O)C1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCN1CCNC(=O)C1 MDRNRIAYLGGFKE-UHFFFAOYSA-N 0.000 claims 2
- OYNIISWIMDFFAF-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCNC(C)=O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCNC(C)=O OYNIISWIMDFFAF-UHFFFAOYSA-N 0.000 claims 2
- RWOWRLYCKOPZHJ-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCO Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCO RWOWRLYCKOPZHJ-UHFFFAOYSA-N 0.000 claims 2
- WMWOLWGPDHWGGI-NRFANRHFSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC[C@@H](O)CC(O)=O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC[C@@H](O)CC(O)=O WMWOLWGPDHWGGI-NRFANRHFSA-N 0.000 claims 2
- JAVOOZFIZRTIMB-SFHVURJKSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@@H](C)C(O)=O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@@H](C)C(O)=O JAVOOZFIZRTIMB-SFHVURJKSA-N 0.000 claims 2
- IDRDYZSWSKCIGO-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)ccc1CN1CCC1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)ccc1CN1CCC1 IDRDYZSWSKCIGO-UHFFFAOYSA-N 0.000 claims 2
- KRAIGCXDUYJGCN-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)ccc1CN1CCCCC1C(O)=O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)ccc1CN1CCCCC1C(O)=O KRAIGCXDUYJGCN-UHFFFAOYSA-N 0.000 claims 2
- IHJYMBHZPIGMGK-SFHVURJKSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)ccc1CN[C@@H](C)C(O)=O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)ccc1CN[C@@H](C)C(O)=O IHJYMBHZPIGMGK-SFHVURJKSA-N 0.000 claims 2
- ZTXIVEFSDGYDHN-GOSISDBHSA-N COc1cccc(c1)-c1cccc(COc2cc(OC)c(CN[C@H](C)C(O)=O)c(OC)c2)c1C Chemical compound COc1cccc(c1)-c1cccc(COc2cc(OC)c(CN[C@H](C)C(O)=O)c(OC)c2)c1C ZTXIVEFSDGYDHN-GOSISDBHSA-N 0.000 claims 2
- RUUNMWXKBFSZIJ-LJQANCHMSA-N C[C@@H](NCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(C)c1)C(O)=O Chemical compound C[C@@H](NCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(C)c1)C(O)=O RUUNMWXKBFSZIJ-LJQANCHMSA-N 0.000 claims 2
- QGXJVELKPSMEGB-QGZVFWFLSA-N C[C@@H](NCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(Cl)c1)C(O)=O Chemical compound C[C@@H](NCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(Cl)c1)C(O)=O QGXJVELKPSMEGB-QGZVFWFLSA-N 0.000 claims 2
- WJLRWTHTEIJWTE-NIYFSFCBSA-N C[C@@H]1C[C@@H](N(Cc2ccc(OCc3cccc(c3C)-c3ccccc3)c(C)c2)C1)C(O)=O Chemical compound C[C@@H]1C[C@@H](N(Cc2ccc(OCc3cccc(c3C)-c3ccccc3)c(C)c2)C1)C(O)=O WJLRWTHTEIJWTE-NIYFSFCBSA-N 0.000 claims 2
- RUUNMWXKBFSZIJ-IBGZPJMESA-N C[C@H](NCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(C)c1)C(O)=O Chemical compound C[C@H](NCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(C)c1)C(O)=O RUUNMWXKBFSZIJ-IBGZPJMESA-N 0.000 claims 2
- QGXJVELKPSMEGB-KRWDZBQOSA-N C[C@H](NCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(Cl)c1)C(O)=O Chemical compound C[C@H](NCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(Cl)c1)C(O)=O QGXJVELKPSMEGB-KRWDZBQOSA-N 0.000 claims 2
- MZGKXSZRBMIMLW-SFHVURJKSA-N C[C@H](NCc1cccc(OCc2cccc(c2C)-c2ccccc2)c1)C(O)=O Chemical compound C[C@H](NCc1cccc(OCc2cccc(c2C)-c2ccccc2)c1)C(O)=O MZGKXSZRBMIMLW-SFHVURJKSA-N 0.000 claims 2
- KQDCXYBUWMBUSN-UHFFFAOYSA-N Cc1c(COc2ccc(CN3CCC(CC3)C(O)=O)cc2Cl)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CN3CCC(CC3)C(O)=O)cc2Cl)cccc1-c1ccccc1 KQDCXYBUWMBUSN-UHFFFAOYSA-N 0.000 claims 2
- GNYIPNWZSMMUFQ-UHFFFAOYSA-N Cc1c(COc2ccc(CN3CCC3)cc2)cccc1-c1ccccc1F Chemical compound Cc1c(COc2ccc(CN3CCC3)cc2)cccc1-c1ccccc1F GNYIPNWZSMMUFQ-UHFFFAOYSA-N 0.000 claims 2
- PRRWLKVPTPBWHS-UHFFFAOYSA-N Cc1c(COc2ccc(CN3CCC3)cc2Br)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CN3CCC3)cc2Br)cccc1-c1ccccc1 PRRWLKVPTPBWHS-UHFFFAOYSA-N 0.000 claims 2
- QRXBPPWUGITQLE-UHFFFAOYSA-N Cc1c(COc2ccc(CN3CCCCC3C(O)=O)cc2Br)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CN3CCCCC3C(O)=O)cc2Br)cccc1-c1ccccc1 QRXBPPWUGITQLE-UHFFFAOYSA-N 0.000 claims 2
- MYHXPAKFKMMKMZ-UHFFFAOYSA-N Cc1c(COc2ccc(CN3CCCCC3C(O)=O)cc2F)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CN3CCCCC3C(O)=O)cc2F)cccc1-c1ccccc1 MYHXPAKFKMMKMZ-UHFFFAOYSA-N 0.000 claims 2
- AAEIUZHZXCPBCS-VWLOTQADSA-N Cc1c(COc2ccc(CN3CCCC[C@H]3C(O)=O)cc2Cl)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CN3CCCC[C@H]3C(O)=O)cc2Cl)cccc1-c1ccccc1 AAEIUZHZXCPBCS-VWLOTQADSA-N 0.000 claims 2
- RVDAEQRWSPNFRG-UHFFFAOYSA-N Cc1c(COc2ccc(CN3CCOCC3C(O)=O)cc2Cl)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CN3CCOCC3C(O)=O)cc2Cl)cccc1-c1ccccc1 RVDAEQRWSPNFRG-UHFFFAOYSA-N 0.000 claims 2
- UXRQTAOAPRKWDQ-UHFFFAOYSA-N Cc1c(COc2ccc(CNC(C)(C)C(O)=O)cc2Cl)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CNC(C)(C)C(O)=O)cc2Cl)cccc1-c1ccccc1 UXRQTAOAPRKWDQ-UHFFFAOYSA-N 0.000 claims 2
- NIVJEFTUALCIHL-UHFFFAOYSA-N Cc1c(COc2ccc(CNCC3CCC(=O)N3)cc2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CNCC3CCC(=O)N3)cc2)cccc1-c1ccccc1 NIVJEFTUALCIHL-UHFFFAOYSA-N 0.000 claims 2
- BJJAFOSFOJOZOO-UHFFFAOYSA-N Cc1c(COc2ccc(CNCCC(N)=O)cc2Br)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CNCCC(N)=O)cc2Br)cccc1-c1ccccc1 BJJAFOSFOJOZOO-UHFFFAOYSA-N 0.000 claims 2
- NUYRSTFEAVNXBY-UHFFFAOYSA-N Cc1c(COc2ccc3CNCCc3c2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc3CNCCc3c2)cccc1-c1ccccc1 NUYRSTFEAVNXBY-UHFFFAOYSA-N 0.000 claims 2
- XQIVBIQDGUDOIA-UHFFFAOYSA-N Cc1c(COc2cccc(CN3CCC3)c2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2cccc(CN3CCC3)c2)cccc1-c1ccccc1 XQIVBIQDGUDOIA-UHFFFAOYSA-N 0.000 claims 2
- VWBHFLZEKIIMQK-UHFFFAOYSA-N Cc1c(COc2cccc(CN3CCCCC3C(O)=O)c2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2cccc(CN3CCCCC3C(O)=O)c2)cccc1-c1ccccc1 VWBHFLZEKIIMQK-UHFFFAOYSA-N 0.000 claims 2
- NZDOPZPDFMPHBL-UHFFFAOYSA-N Cc1c(COc2cccc(CNCCC(N)=O)c2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2cccc(CNCCC(N)=O)c2)cccc1-c1ccccc1 NZDOPZPDFMPHBL-UHFFFAOYSA-N 0.000 claims 2
- CUVBOKMETMPOEM-UHFFFAOYSA-N Cc1cc(CN2CCC(CC2)C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 Chemical compound Cc1cc(CN2CCC(CC2)C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 CUVBOKMETMPOEM-UHFFFAOYSA-N 0.000 claims 2
- YWANNZJYJLPFKV-UHFFFAOYSA-N Cc1cc(CN2CCCC2C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 Chemical compound Cc1cc(CN2CCCC2C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 YWANNZJYJLPFKV-UHFFFAOYSA-N 0.000 claims 2
- DIEFHARFEOYRCE-UHFFFAOYSA-N Cc1cc(CN2CCCCC2C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 Chemical compound Cc1cc(CN2CCCCC2C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 DIEFHARFEOYRCE-UHFFFAOYSA-N 0.000 claims 2
- CWKDBXPHEHNUTI-UHFFFAOYSA-N Cc1cc(CN2CCCCC2CC(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 Chemical compound Cc1cc(CN2CCCCC2CC(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 CWKDBXPHEHNUTI-UHFFFAOYSA-N 0.000 claims 2
- YSKRXTFVLTYIRJ-UHFFFAOYSA-N Cc1cc(CN2CCCCCC2C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 Chemical compound Cc1cc(CN2CCCCCC2C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 YSKRXTFVLTYIRJ-UHFFFAOYSA-N 0.000 claims 2
- DIEFHARFEOYRCE-AREMUKBSSA-N Cc1cc(CN2CCCC[C@@H]2C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 Chemical compound Cc1cc(CN2CCCC[C@@H]2C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 DIEFHARFEOYRCE-AREMUKBSSA-N 0.000 claims 2
- DIEFHARFEOYRCE-SANMLTNESA-N Cc1cc(CN2CCCC[C@H]2C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 Chemical compound Cc1cc(CN2CCCC[C@H]2C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 DIEFHARFEOYRCE-SANMLTNESA-N 0.000 claims 2
- YWANNZJYJLPFKV-RUZDIDTESA-N Cc1cc(CN2CCC[C@@H]2C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 Chemical compound Cc1cc(CN2CCC[C@@H]2C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 YWANNZJYJLPFKV-RUZDIDTESA-N 0.000 claims 2
- CSGXVUMLNZXMMP-XMMPIXPASA-N Cc1cc(CN2CCC[C@H](C2)C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 Chemical compound Cc1cc(CN2CCC[C@H](C2)C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 CSGXVUMLNZXMMP-XMMPIXPASA-N 0.000 claims 2
- RJBDMKDUAKYPMJ-VWLOTQADSA-N Cc1cc(CN2CCC[C@H]2CO)ccc1OCc1cccc(c1C)-c1ccccc1 Chemical compound Cc1cc(CN2CCC[C@H]2CO)ccc1OCc1cccc(c1C)-c1ccccc1 RJBDMKDUAKYPMJ-VWLOTQADSA-N 0.000 claims 2
- CORBBPZHTZEDTN-DEOSSOPVSA-N Cc1cc(CN2CC[C@H]2C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 Chemical compound Cc1cc(CN2CC[C@H]2C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 CORBBPZHTZEDTN-DEOSSOPVSA-N 0.000 claims 2
- IDIOAIIUPDWEBC-UHFFFAOYSA-N Cc1cc(CNCC2CCC(=O)N2)ccc1OCc1cccc(c1C)-c1ccccc1 Chemical compound Cc1cc(CNCC2CCC(=O)N2)ccc1OCc1cccc(c1C)-c1ccccc1 IDIOAIIUPDWEBC-UHFFFAOYSA-N 0.000 claims 2
- MRKKHKMPJRIIPU-UHFFFAOYSA-N Cc1cc(CNCCO)ccc1OCc1cccc(c1C)-c1ccccc1 Chemical compound Cc1cc(CNCCO)ccc1OCc1cccc(c1C)-c1ccccc1 MRKKHKMPJRIIPU-UHFFFAOYSA-N 0.000 claims 2
- OAHMJAXIBOFXIV-UHFFFAOYSA-N Cc1cc(OCc2cccc(c2C)-c2ccccc2)cc(C)c1CN1CCCCC1C(O)=O Chemical compound Cc1cc(OCc2cccc(c2C)-c2ccccc2)cc(C)c1CN1CCCCC1C(O)=O OAHMJAXIBOFXIV-UHFFFAOYSA-N 0.000 claims 2
- XVKKAAVWQFLMPI-UHFFFAOYSA-N Cc1cc(OCc2cccc(c2C)-c2ccccc2)cc(C)c1CNCCC(N)=O Chemical compound Cc1cc(OCc2cccc(c2C)-c2ccccc2)cc(C)c1CNCCC(N)=O XVKKAAVWQFLMPI-UHFFFAOYSA-N 0.000 claims 2
- JKXLTFJHXCHRMA-UHFFFAOYSA-N N-(2-hydroxyethyl)-1-[[2-methoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]piperidine-4-carboxamide Chemical compound COC1=CC(OCC2=C(C)C(=CC=C2)C2=CC=CC=C2)=CC=C1CN1CCC(CC1)C(=O)NCCO JKXLTFJHXCHRMA-UHFFFAOYSA-N 0.000 claims 2
- GOBRMVNDDYLBKD-UHFFFAOYSA-N N-[2-[1-[3-methyl-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]ethylamino]ethyl]acetamide Chemical compound CC(NCCNC(C)=O)c1ccc(OCc2cccc(c2C)-c2ccccc2)c(C)c1 GOBRMVNDDYLBKD-UHFFFAOYSA-N 0.000 claims 2
- ZFZHQQVOKKIXPI-UHFFFAOYSA-N N-[2-[[2,6-dimethyl-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]ethyl]acetamide Chemical compound CC(=O)NCCNCc1c(C)cc(OCc2cccc(c2C)-c2ccccc2)cc1C ZFZHQQVOKKIXPI-UHFFFAOYSA-N 0.000 claims 2
- KHSZKUGLGOCHDC-UHFFFAOYSA-N N-[2-[[3-chloro-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]ethyl]acetamide Chemical compound CC(=O)NCCNCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(Cl)c1 KHSZKUGLGOCHDC-UHFFFAOYSA-N 0.000 claims 2
- JOQZFJRPPIMBNA-UHFFFAOYSA-N N-[2-[[4-methyl-3-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]ethyl]acetamide Chemical compound CC(=O)NCCNCc1ccc(C)c(OCc2cccc(c2C)-c2ccccc2)c1 JOQZFJRPPIMBNA-UHFFFAOYSA-N 0.000 claims 2
- KIUSCCDCOPAXCS-UHFFFAOYSA-N N-[2-[[5-[(2-methyl-3-phenylphenyl)methoxy]-1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-1-yl]amino]ethyl]acetamide Chemical compound CC(=O)NCCNC1CCCC2C(CCCC12)OCc1cccc(c1C)-c1ccccc1 KIUSCCDCOPAXCS-UHFFFAOYSA-N 0.000 claims 2
- UAKMDFGBYWWAOW-UHFFFAOYSA-N N-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]-2-(4-methylpiperazin-1-yl)ethanamine Chemical compound COC1=CC(OCC2=C(C)C(=CC=C2)C2=CC=CC=C2)=CC(OC)=C1CNCCN1CCN(C)CC1 UAKMDFGBYWWAOW-UHFFFAOYSA-N 0.000 claims 2
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N gamma-butyrolactam Natural products O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 claims 2
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 2
- SFVBPSWRCHUWMF-LJAQVGFWSA-N (1R)-2-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]-1-phenylethanol Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC[C@H](O)c1ccccc1 SFVBPSWRCHUWMF-LJAQVGFWSA-N 0.000 claims 1
- WRWPUUKELJIWHM-KAYWLYCHSA-N (1R,2R)-2-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]cyclohexan-1-ol Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@@H]1CCCC[C@H]1O WRWPUUKELJIWHM-KAYWLYCHSA-N 0.000 claims 1
- VQHLTBODBCNTSO-CLJLJLNGSA-N (1R,2R)-2-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]cyclopentan-1-ol Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CN[C@H]1[C@@H](CCC1)O VQHLTBODBCNTSO-CLJLJLNGSA-N 0.000 claims 1
- AKJGZMYBHGRGOU-KAYWLYCHSA-N (1R,2R)-2-[[3-methyl-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]cyclohexan-1-ol Chemical compound Cc1cc(CN[C@@H]2CCCC[C@H]2O)ccc1OCc1cccc(c1C)-c1ccccc1 AKJGZMYBHGRGOU-KAYWLYCHSA-N 0.000 claims 1
- VQHLTBODBCNTSO-IZZNHLLZSA-N (1R,2S)-2-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]cyclopentan-1-ol Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CN[C@@H]1[C@@H](CCC1)O VQHLTBODBCNTSO-IZZNHLLZSA-N 0.000 claims 1
- SFVBPSWRCHUWMF-GDLZYMKVSA-N (1S)-2-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]-1-phenylethanol Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CNC[C@@H](O)C1=CC=CC=C1 SFVBPSWRCHUWMF-GDLZYMKVSA-N 0.000 claims 1
- WRWPUUKELJIWHM-SXOMAYOGSA-N (1S,2R)-2-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]cyclohexan-1-ol Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CN[C@H]1[C@H](CCCC1)O WRWPUUKELJIWHM-SXOMAYOGSA-N 0.000 claims 1
- VQHLTBODBCNTSO-UIOOFZCWSA-N (1S,2S)-2-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]cyclopentan-1-ol Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CN[C@@H]1[C@H](CCC1)O VQHLTBODBCNTSO-UIOOFZCWSA-N 0.000 claims 1
- CEENJLDDMBNKDX-SFHVURJKSA-N (2S)-1-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]propan-2-ol Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC[C@H](C)O CEENJLDDMBNKDX-SFHVURJKSA-N 0.000 claims 1
- WIPLIOVSJOEWFD-SANMLTNESA-N (2S)-1-[[4-[(2-cyano-3-phenylphenyl)methoxy]-2,6-dimethoxyphenyl]methyl]piperidine-2-carboxylic acid Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCCC[C@H]1C(O)=O WIPLIOVSJOEWFD-SANMLTNESA-N 0.000 claims 1
- DUQNSDJAPIRMFA-VWLOTQADSA-N (2S)-1-[[4-[(2-cyano-3-phenylphenyl)methoxy]-2,6-dimethoxyphenyl]methyl]pyrrolidine-2-carboxamide Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCC[C@H]1C(N)=O DUQNSDJAPIRMFA-VWLOTQADSA-N 0.000 claims 1
- OLSHCRHDCVPQRJ-VWLOTQADSA-N (2S)-1-[[4-[[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methoxy]-2,5-difluorophenyl]methyl]piperidine-2-carboxylic acid Chemical compound Cc1c(COc2cc(F)c(CN3CCCC[C@H]3C(O)=O)cc2F)cccc1-c1ccc2OCCOc2c1 OLSHCRHDCVPQRJ-VWLOTQADSA-N 0.000 claims 1
- BXTVOBAMQXQEKX-NRFANRHFSA-N (3S)-4-[[3-[[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methoxy]-4-(trifluoromethyl)phenyl]methylamino]-3-hydroxybutanoic acid Chemical compound C1=C(C=CC2=C1OCCO2)C1=C(C)C(COC2=C(C(F)(F)F)C=CC(CNC[C@@H](O)CC(=O)O)=C2)=CC=C1 BXTVOBAMQXQEKX-NRFANRHFSA-N 0.000 claims 1
- SSNAOTQAARBFBK-QHCPKHFHSA-N (5S)-6-[[3-chloro-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]-1,2,6-triazaspiro[2.4]hept-1-ene-5-carboxylic acid Chemical compound Cc1c(COc2ccc(CN3CC4(C[C@H]3C(O)=O)N=N4)cc2Cl)cccc1-c1ccccc1 SSNAOTQAARBFBK-QHCPKHFHSA-N 0.000 claims 1
- RZNHHGMCDDENDY-UHFFFAOYSA-N 1-(1-methylimidazol-2-yl)ethanol Chemical compound CC(O)C1=NC=CN1C RZNHHGMCDDENDY-UHFFFAOYSA-N 0.000 claims 1
- DTUSUTVQIDPUBP-UHFFFAOYSA-N 1-(3,3-difluorocyclobutyl)-N-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]methanamine Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC1CC(F)(F)C1 DTUSUTVQIDPUBP-UHFFFAOYSA-N 0.000 claims 1
- KQJHCDPRKVWRIW-UHFFFAOYSA-N 1-[2-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]ethyl]piperidin-4-ol Chemical compound COC1=CC(OCC2=C(C)C(=CC=C2)C2=CC=CC=C2)=CC(OC)=C1CNCCN1CCC(O)CC1 KQJHCDPRKVWRIW-UHFFFAOYSA-N 0.000 claims 1
- DJUFRQIDQIJLHB-UHFFFAOYSA-N 1-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]-2,3-dihydro-1H-inden-2-ol Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC1C(O)Cc2ccccc12 DJUFRQIDQIJLHB-UHFFFAOYSA-N 0.000 claims 1
- TWZSQHIJRXGXTC-UHFFFAOYSA-N 1-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]-3-(dimethylamino)propan-2-ol Chemical compound COC1=CC(OCC2=C(C)C(=CC=C2)C2=CC=CC=C2)=CC(OC)=C1CNCC(O)CN(C)C TWZSQHIJRXGXTC-UHFFFAOYSA-N 0.000 claims 1
- SNCZXWJNFAMFMM-UHFFFAOYSA-N 1-[[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]methyl]cyclobutan-1-ol Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CNCC1(CCC1)O SNCZXWJNFAMFMM-UHFFFAOYSA-N 0.000 claims 1
- DXRWTYQYYIQFFT-UHFFFAOYSA-N 1-[[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]methyl]cyclohexan-1-ol Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CNCC1(CCCCC1)O DXRWTYQYYIQFFT-UHFFFAOYSA-N 0.000 claims 1
- JZEMKIVQTLMDHR-UHFFFAOYSA-N 2-[2-[2-[2-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CNCCOCCOCCOCCO JZEMKIVQTLMDHR-UHFFFAOYSA-N 0.000 claims 1
- KFGVVLYYXUEFDP-UHFFFAOYSA-N 2-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]-1-morpholin-4-ylethanone Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC(=O)N1CCOCC1 KFGVVLYYXUEFDP-UHFFFAOYSA-N 0.000 claims 1
- UNAUEYAHPNNWAF-UHFFFAOYSA-N 2-[[2-[[2-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]acetyl]amino]acetyl]amino]-4-methylpentanoic acid Chemical compound COC1=CC(OCC2=C(C)C(=CC=C2)C2=CC=CC=C2)=CC(OC)=C1CNCC(=O)NCC(=O)NC(CC(C)C)C(O)=O UNAUEYAHPNNWAF-UHFFFAOYSA-N 0.000 claims 1
- QRMQMJWZVFRNAG-UHFFFAOYSA-N 2-[[3,5-dimethoxy-4-[(2-morpholin-4-ylethylamino)methyl]phenoxy]methyl]-6-phenylbenzonitrile Chemical compound COC1=CC(OCC2=C(C#N)C(=CC=C2)C2=CC=CC=C2)=CC(OC)=C1CNCCN1CCOCC1 QRMQMJWZVFRNAG-UHFFFAOYSA-N 0.000 claims 1
- BOJXYPQIHZTTTA-UHFFFAOYSA-N 2-[[4-[[(3-hydroxyphenyl)methylamino]methyl]-3,5-dimethoxyphenoxy]methyl]-6-phenylbenzonitrile Chemical compound OC=1C=C(C=CC1)CNCC1=C(C=C(OCC2=C(C#N)C(=CC=C2)C2=CC=CC=C2)C=C1OC)OC BOJXYPQIHZTTTA-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001845 4 membered carbocyclic group Chemical group 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- DKIHTVJLLXJMSG-UHFFFAOYSA-N C(C)OC=1C=C(C=CC1)C=1C(=C(C=CC1)COC1=CC(=C(C(=C1)OC)CNCCO)OC)C Chemical compound C(C)OC=1C=C(C=CC1)C=1C(=C(C=CC1)COC1=CC(=C(C(=C1)OC)CNCCO)OC)C DKIHTVJLLXJMSG-UHFFFAOYSA-N 0.000 claims 1
- WSXQIOJWUBTTFX-UHFFFAOYSA-N CC(=O)NCCNCc1cc(F)c(OCc2cccc(c2C)-c2ccc3OCCOc3c2)cc1F Chemical compound CC(=O)NCCNCc1cc(F)c(OCc2cccc(c2C)-c2ccc3OCCOc3c2)cc1F WSXQIOJWUBTTFX-UHFFFAOYSA-N 0.000 claims 1
- UUSQAZRMMMADQG-UHFFFAOYSA-N CC(=O)NCCNCc1ccc(OCc2cccc(-c3ccsc3)c2C)c(Cl)c1 Chemical compound CC(=O)NCCNCc1ccc(OCc2cccc(-c3ccsc3)c2C)c(Cl)c1 UUSQAZRMMMADQG-UHFFFAOYSA-N 0.000 claims 1
- NCBPLPAJPNAHOU-UHFFFAOYSA-N CC(=O)NCCNCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(c1)C#N Chemical compound CC(=O)NCCNCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(c1)C#N NCBPLPAJPNAHOU-UHFFFAOYSA-N 0.000 claims 1
- VEKXNMUQKQJTPG-DEOSSOPVSA-N CC(=O)N[C@H]1CCN(Cc2ccc(OCc3cccc(c3C)-c3ccccc3)nc2)C1 Chemical compound CC(=O)N[C@H]1CCN(Cc2ccc(OCc3cccc(c3C)-c3ccccc3)nc2)C1 VEKXNMUQKQJTPG-DEOSSOPVSA-N 0.000 claims 1
- QOWSWLSZQBUTJS-UHFFFAOYSA-N CC(C)NCc1ccc(OCc2cccc(c2C)-c2ccccc2)nc1 Chemical compound CC(C)NCc1ccc(OCc2cccc(c2C)-c2ccccc2)nc1 QOWSWLSZQBUTJS-UHFFFAOYSA-N 0.000 claims 1
- XHPSMNJXCNQKAI-UHFFFAOYSA-N CC1=C(C=CC=C1C1=CC=CC=C1)COC1=CC=C(C=N1)CN1CC(CCC1)CO Chemical compound CC1=C(C=CC=C1C1=CC=CC=C1)COC1=CC=C(C=N1)CN1CC(CCC1)CO XHPSMNJXCNQKAI-UHFFFAOYSA-N 0.000 claims 1
- IYJOLXWUSHNQMX-UHFFFAOYSA-N CC1=C(C=CC=C1C1=CC=CC=C1)COC1=CC=C(C=N1)CNCC1CCC(N1)=O Chemical compound CC1=C(C=CC=C1C1=CC=CC=C1)COC1=CC=C(C=N1)CNCC1CCC(N1)=O IYJOLXWUSHNQMX-UHFFFAOYSA-N 0.000 claims 1
- IANIEFFEUVFFNI-UHFFFAOYSA-N CC1=C(C=CC=C1C1=CC=CC=C1)COC=1C=CC(=NC1)CNCC1CCC(N1)=O Chemical compound CC1=C(C=CC=C1C1=CC=CC=C1)COC=1C=CC(=NC1)CNCC1CCC(N1)=O IANIEFFEUVFFNI-UHFFFAOYSA-N 0.000 claims 1
- VMPHLMLKSUYKMI-UHFFFAOYSA-N CC1=C(COC2=NC=C(CNCCC3=CC=CC=N3)C=C2)C=CC=C1C1=CC=CC=C1 Chemical compound CC1=C(COC2=NC=C(CNCCC3=CC=CC=N3)C=C2)C=CC=C1C1=CC=CC=C1 VMPHLMLKSUYKMI-UHFFFAOYSA-N 0.000 claims 1
- MCUFBZCYIIVJOM-UHFFFAOYSA-N CC1CCCN1Cc1ccc(OCc2cccc(c2C)-c2ccccc2)nc1 Chemical compound CC1CCCN1Cc1ccc(OCc2cccc(c2C)-c2ccccc2)nc1 MCUFBZCYIIVJOM-UHFFFAOYSA-N 0.000 claims 1
- XDCCQJYWWJAQMF-UHFFFAOYSA-N CCC(CO)(CO)NCc1c(OC)cc(OCc2cccc(c2C)-c2ccccc2)cc1OC Chemical compound CCC(CO)(CO)NCc1c(OC)cc(OCc2cccc(c2C)-c2ccccc2)cc1OC XDCCQJYWWJAQMF-UHFFFAOYSA-N 0.000 claims 1
- IYWXJKHOWWHWCT-QHCPKHFHSA-N CCC[C@@H](CO)NCc1c(OC)cc(OCc2cccc(c2C)-c2ccccc2)cc1OC Chemical compound CCC[C@@H](CO)NCc1c(OC)cc(OCc2cccc(c2C)-c2ccccc2)cc1OC IYWXJKHOWWHWCT-QHCPKHFHSA-N 0.000 claims 1
- BNGQQIPGCOKIDI-UHFFFAOYSA-N CCN(Cc1ccncc1)Cc1c(OC)cc(OCc2cccc(-c3ccccc3)c2C#N)cc1OC Chemical compound CCN(Cc1ccncc1)Cc1c(OC)cc(OCc2cccc(-c3ccccc3)c2C#N)cc1OC BNGQQIPGCOKIDI-UHFFFAOYSA-N 0.000 claims 1
- DIRXBWVQQFYQNE-QFIPXVFZSA-N CC[C@@H](CO)NCc1c(OC)cc(OCc2cccc(c2C)-c2ccccc2)cc1OC Chemical compound CC[C@@H](CO)NCc1c(OC)cc(OCc2cccc(c2C)-c2ccccc2)cc1OC DIRXBWVQQFYQNE-QFIPXVFZSA-N 0.000 claims 1
- YVKQJGZGAFOCNM-MUUNZHRXSA-N CC[C@@](C)(NCc1c(OC)cc(OCc2cccc(c2C)-c2ccccc2)cc1OC)C(O)=O Chemical compound CC[C@@](C)(NCc1c(OC)cc(OCc2cccc(c2C)-c2ccccc2)cc1OC)C(O)=O YVKQJGZGAFOCNM-MUUNZHRXSA-N 0.000 claims 1
- DIRXBWVQQFYQNE-JOCHJYFZSA-N CC[C@H](CO)NCc1c(OC)cc(OCc2cccc(c2C)-c2ccccc2)cc1OC Chemical compound CC[C@H](CO)NCc1c(OC)cc(OCc2cccc(c2C)-c2ccccc2)cc1OC DIRXBWVQQFYQNE-JOCHJYFZSA-N 0.000 claims 1
- SILBJAGFZQLCDJ-UHFFFAOYSA-N CN(C)CCNCc1ccc(OCc2cccc(c2C)-c2ccccc2)nc1 Chemical compound CN(C)CCNCc1ccc(OCc2cccc(c2C)-c2ccccc2)nc1 SILBJAGFZQLCDJ-UHFFFAOYSA-N 0.000 claims 1
- ZMKNXRAVJZZCKX-UHFFFAOYSA-N CNCC1=NC=C(C=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C Chemical compound CNCC1=NC=C(C=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C ZMKNXRAVJZZCKX-UHFFFAOYSA-N 0.000 claims 1
- KIDRVOUEZVIKBH-UHFFFAOYSA-N CNCC=1C=NC(=CC1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C Chemical compound CNCC=1C=NC(=CC1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C KIDRVOUEZVIKBH-UHFFFAOYSA-N 0.000 claims 1
- WJZZOTQYDJBATG-UHFFFAOYSA-N CNCc1c(OC)cc(OCc2cccc(-c3ccccc3)c2C#N)cc1OC Chemical compound CNCc1c(OC)cc(OCc2cccc(-c3ccccc3)c2C#N)cc1OC WJZZOTQYDJBATG-UHFFFAOYSA-N 0.000 claims 1
- CTJHSDXJXRVNNY-UHFFFAOYSA-N COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC(=CC=C1)OC)C)OC)CNCCNC(C)=O Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC(=CC=C1)OC)C)OC)CNCCNC(C)=O CTJHSDXJXRVNNY-UHFFFAOYSA-N 0.000 claims 1
- UAQKTBHPBCTFAG-UHFFFAOYSA-N COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC(=CC=C1)OCCC)C)OC)CNCCO Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC(=CC=C1)OCCC)C)OC)CNCCO UAQKTBHPBCTFAG-UHFFFAOYSA-N 0.000 claims 1
- POGRFIHBWGRXKQ-DEOSSOPVSA-N COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CN1CC2(N=N2)C[C@H]1C(=O)O Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CN1CC2(N=N2)C[C@H]1C(=O)O POGRFIHBWGRXKQ-DEOSSOPVSA-N 0.000 claims 1
- ZUNMRCWDGXBLHY-UHFFFAOYSA-N COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CNC(C(C)(O)C)C Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CNC(C(C)(O)C)C ZUNMRCWDGXBLHY-UHFFFAOYSA-N 0.000 claims 1
- JUKIXKGNADUBQZ-UHFFFAOYSA-N COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CNC(C(C)O)C Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CNC(C(C)O)C JUKIXKGNADUBQZ-UHFFFAOYSA-N 0.000 claims 1
- FDNLSOYPUAARJN-UHFFFAOYSA-N COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CNC1(CCCC1)CO Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CNC1(CCCC1)CO FDNLSOYPUAARJN-UHFFFAOYSA-N 0.000 claims 1
- ZMJPFJUFCAOCCS-UHFFFAOYSA-N COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CNCC(CC)O Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CNCC(CC)O ZMJPFJUFCAOCCS-UHFFFAOYSA-N 0.000 claims 1
- BBYOBMYDDHSXDT-LJAQVGFWSA-N COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CN[C@@H](CO)C1=CC=CC=C1 Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CN[C@@H](CO)C1=CC=CC=C1 BBYOBMYDDHSXDT-LJAQVGFWSA-N 0.000 claims 1
- BBYOBMYDDHSXDT-GDLZYMKVSA-N COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CN[C@H](CO)C1=CC=CC=C1 Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CN[C@H](CO)C1=CC=CC=C1 BBYOBMYDDHSXDT-GDLZYMKVSA-N 0.000 claims 1
- RKUORYVPLXYDFJ-DEOSSOPVSA-N COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CN[C@H](CO)CC(C)C Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CN[C@H](CO)CC(C)C RKUORYVPLXYDFJ-DEOSSOPVSA-N 0.000 claims 1
- FVRCXSDISSVNBG-CCLHPLFOSA-N COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CN[C@H](CO)[C@H](CC)C Chemical compound COC1=C(C(=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)OC)CN[C@H](CO)[C@H](CC)C FVRCXSDISSVNBG-CCLHPLFOSA-N 0.000 claims 1
- HIUGGNBVKQUYKF-UHFFFAOYSA-N COC1=CC(OCC2=C(C)C(=CC=C2)C2=CC=CC=C2)=CC(OC)=C1CN1CCC(O)(CC1)C(N)=O Chemical compound COC1=CC(OCC2=C(C)C(=CC=C2)C2=CC=CC=C2)=CC(OC)=C1CN1CCC(O)(CC1)C(N)=O HIUGGNBVKQUYKF-UHFFFAOYSA-N 0.000 claims 1
- RLERFXIAHSTVIC-UHFFFAOYSA-N COC=1C=C(OCC2=C(C#N)C(=CC=C2)C2=CC=CC=C2)C=C(C=1CNCCCN1C(CCC1)=O)OC Chemical compound COC=1C=C(OCC2=C(C#N)C(=CC=C2)C2=CC=CC=C2)C=C(C=1CNCCCN1C(CCC1)=O)OC RLERFXIAHSTVIC-UHFFFAOYSA-N 0.000 claims 1
- AJXZPCIOBVYETD-UHFFFAOYSA-N COCCNCc1c(OC)cc(OCc2cccc(-c3ccccc3)c2C#N)cc1OC Chemical compound COCCNCc1c(OC)cc(OCc2cccc(-c3ccccc3)c2C#N)cc1OC AJXZPCIOBVYETD-UHFFFAOYSA-N 0.000 claims 1
- JPKMBXLSPLEASY-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1C(C)CCC1C Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1C(C)CCC1C JPKMBXLSPLEASY-UHFFFAOYSA-N 0.000 claims 1
- SWFHZGGDTJIWSZ-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCC1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCC1 SWFHZGGDTJIWSZ-UHFFFAOYSA-N 0.000 claims 1
- MERHIOAGOUDOLD-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCCC(C)C1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCCC(C)C1 MERHIOAGOUDOLD-UHFFFAOYSA-N 0.000 claims 1
- QHXJQISIDOZJGJ-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCCC(C1)C(O)=O Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCCC(C1)C(O)=O QHXJQISIDOZJGJ-UHFFFAOYSA-N 0.000 claims 1
- KXYPOJZVZOGBNM-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCCC(CO)C1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCCC(CO)C1 KXYPOJZVZOGBNM-UHFFFAOYSA-N 0.000 claims 1
- LFGLHVLFNPRWNU-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCCC(O)C1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCCC(O)C1 LFGLHVLFNPRWNU-UHFFFAOYSA-N 0.000 claims 1
- FDGUMKDXNMDZDZ-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCCC1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCCC1 FDGUMKDXNMDZDZ-UHFFFAOYSA-N 0.000 claims 1
- XWUQRTVSRZAOHT-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCCC1C Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCCC1C XWUQRTVSRZAOHT-UHFFFAOYSA-N 0.000 claims 1
- VOUQQSDINWYWOT-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCCN(CC1)C(C)=O Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCCN(CC1)C(C)=O VOUQQSDINWYWOT-UHFFFAOYSA-N 0.000 claims 1
- HOWNMIDVPXVJME-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCN(CC1)C(C)=O Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCN(CC1)C(C)=O HOWNMIDVPXVJME-UHFFFAOYSA-N 0.000 claims 1
- JCRRGWHYBLZCAI-QHCPKHFHSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CC[C@@H](C1)NC(C)=O Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CC[C@@H](C1)NC(C)=O JCRRGWHYBLZCAI-QHCPKHFHSA-N 0.000 claims 1
- HXEHEBWGBFEGHH-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNC(C)C Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNC(C)C HXEHEBWGBFEGHH-UHFFFAOYSA-N 0.000 claims 1
- AAJPIEJWNVYMGO-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNC1(CO)CCCC1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNC1(CO)CCCC1 AAJPIEJWNVYMGO-UHFFFAOYSA-N 0.000 claims 1
- WXUVTCGMSMFVBQ-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNC1CC1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNC1CC1 WXUVTCGMSMFVBQ-UHFFFAOYSA-N 0.000 claims 1
- GVKRIBKIAGEUGE-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNC1CCC(O)CC1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNC1CCC(O)CC1 GVKRIBKIAGEUGE-UHFFFAOYSA-N 0.000 claims 1
- WYHIHFMIMJWJKF-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNC1CCC1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNC1CCC1 WYHIHFMIMJWJKF-UHFFFAOYSA-N 0.000 claims 1
- MLGYDLQNIZYLAH-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNC1CCCC1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNC1CCCC1 MLGYDLQNIZYLAH-UHFFFAOYSA-N 0.000 claims 1
- IOUNFTFULVKAND-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNC1CCCCC1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNC1CCCCC1 IOUNFTFULVKAND-UHFFFAOYSA-N 0.000 claims 1
- FKVGEVWPIYZSRP-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCCC(N)=O Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCCC(N)=O FKVGEVWPIYZSRP-UHFFFAOYSA-N 0.000 claims 1
- FOQIRHYDHROHMG-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCCN(C)C Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCCN(C)C FOQIRHYDHROHMG-UHFFFAOYSA-N 0.000 claims 1
- AQMDRMVAHPBQKI-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCCN1CCCC1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCCN1CCCC1 AQMDRMVAHPBQKI-UHFFFAOYSA-N 0.000 claims 1
- KXDLFZSSQMCMOM-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCCNC(C)=O Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCCNC(C)=O KXDLFZSSQMCMOM-UHFFFAOYSA-N 0.000 claims 1
- CRXMIYGHZKOKII-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCCO Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCCO CRXMIYGHZKOKII-UHFFFAOYSA-N 0.000 claims 1
- AVTPGUBVEFQMJW-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCCc1ccccn1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCCc1ccccn1 AVTPGUBVEFQMJW-UHFFFAOYSA-N 0.000 claims 1
- SGRJFBMMKOAXCG-FQEVSTJZSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNC[C@@H](O)CC(O)=O Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNC[C@@H](O)CC(O)=O SGRJFBMMKOAXCG-FQEVSTJZSA-N 0.000 claims 1
- PQKOCOSLDBIXGO-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCc1ccc(O)cc1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCc1ccc(O)cc1 PQKOCOSLDBIXGO-UHFFFAOYSA-N 0.000 claims 1
- CEZBHLMYSJAGKM-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCc1ccccc1O Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCc1ccccc1O CEZBHLMYSJAGKM-UHFFFAOYSA-N 0.000 claims 1
- LCRFCTGUHUMZMO-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCc1ccccn1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCc1ccccn1 LCRFCTGUHUMZMO-UHFFFAOYSA-N 0.000 claims 1
- GDZHIPBAWRVMMO-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCc1cccnc1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCc1cccnc1 GDZHIPBAWRVMMO-UHFFFAOYSA-N 0.000 claims 1
- IMQYUPOKVQUSJL-UHFFFAOYSA-N COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCc1ccncc1 Chemical compound COc1cc(OCc2cccc(-c3ccccc3)c2C#N)cc(OC)c1CNCc1ccncc1 IMQYUPOKVQUSJL-UHFFFAOYSA-N 0.000 claims 1
- HPRGLYMHZHSKBH-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccc3OCOc3c2)cc(OC)c1CNCCNC(C)=O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccc3OCOc3c2)cc(OC)c1CNCCNC(C)=O HPRGLYMHZHSKBH-UHFFFAOYSA-N 0.000 claims 1
- YBEKTEZOCIZYAS-QGZVFWFLSA-N COc1cc(OCc2cccc(c2C)-c2ccc3OCOc3c2)cc(OC)c1CN[C@H](C)C(O)=O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccc3OCOc3c2)cc(OC)c1CN[C@H](C)C(O)=O YBEKTEZOCIZYAS-QGZVFWFLSA-N 0.000 claims 1
- RREDZXHJHHGGPH-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2cccc(OCCN3CCCCC3)c2)cc(OC)c1CNCCO Chemical compound COc1cc(OCc2cccc(c2C)-c2cccc(OCCN3CCCCC3)c2)cc(OC)c1CNCCO RREDZXHJHHGGPH-UHFFFAOYSA-N 0.000 claims 1
- DRWOHNQSHPINSR-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN(C)CCN Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN(C)CCN DRWOHNQSHPINSR-UHFFFAOYSA-N 0.000 claims 1
- PIDMKJMRHQPMGX-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN(C)CCNC(=O)C=C Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN(C)CCNC(=O)C=C PIDMKJMRHQPMGX-UHFFFAOYSA-N 0.000 claims 1
- RZHFWCSDOHHISF-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN(C)CCNC(=O)Nc1ccccc1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN(C)CCNC(=O)Nc1ccccc1 RZHFWCSDOHHISF-UHFFFAOYSA-N 0.000 claims 1
- AQRBSBISBBOZLF-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN(C)CCNS(=O)(=O)c1ccc2oc(=O)ccc2c1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN(C)CCNS(=O)(=O)c1ccc2oc(=O)ccc2c1 AQRBSBISBBOZLF-UHFFFAOYSA-N 0.000 claims 1
- OMUATABPOVWGRI-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC(C)(CO)CO Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC(C)(CO)CO OMUATABPOVWGRI-UHFFFAOYSA-N 0.000 claims 1
- FBYCPLYEOZCMPR-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC(CO)(CO)CO Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC(CO)(CO)CO FBYCPLYEOZCMPR-UHFFFAOYSA-N 0.000 claims 1
- AIKKOMTXOJSVJD-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC(CO)CO Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC(CO)CO AIKKOMTXOJSVJD-UHFFFAOYSA-N 0.000 claims 1
- HRMDXCZCDYGFEF-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC1(CO)CCOCC1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC1(CO)CCOCC1 HRMDXCZCDYGFEF-UHFFFAOYSA-N 0.000 claims 1
- WRWPUUKELJIWHM-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC1CCCCC1O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC1CCCCC1O WRWPUUKELJIWHM-UHFFFAOYSA-N 0.000 claims 1
- QEIVNKBIQAKCGX-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC(=O)NCC(=O)NCC(O)=O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC(=O)NCC(=O)NCC(O)=O QEIVNKBIQAKCGX-UHFFFAOYSA-N 0.000 claims 1
- OGRUEURUYCNGAA-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC(C)(C)O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC(C)(C)O OGRUEURUYCNGAA-UHFFFAOYSA-N 0.000 claims 1
- CEENJLDDMBNKDX-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC(C)O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC(C)O CEENJLDDMBNKDX-UHFFFAOYSA-N 0.000 claims 1
- QDARKWLJSKZFNV-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC(O)C(C)C Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC(O)C(C)C QDARKWLJSKZFNV-UHFFFAOYSA-N 0.000 claims 1
- YZWKTZFBUDURFM-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC(O)c1cccnc1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC(O)c1cccnc1 YZWKTZFBUDURFM-UHFFFAOYSA-N 0.000 claims 1
- MMFLNKBJUGWDQC-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC(O)c1ccncc1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC(O)c1ccncc1 MMFLNKBJUGWDQC-UHFFFAOYSA-N 0.000 claims 1
- JODQGIBYHKTBAA-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC1(O)CCN(C)CC1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC1(O)CCN(C)CC1 JODQGIBYHKTBAA-UHFFFAOYSA-N 0.000 claims 1
- YLXAVKAGODUILD-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC1CC(=O)N1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC1CC(=O)N1 YLXAVKAGODUILD-UHFFFAOYSA-N 0.000 claims 1
- UZBQQSTXSUBWFF-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC1CCC1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCC1CCC1 UZBQQSTXSUBWFF-UHFFFAOYSA-N 0.000 claims 1
- GHTNSXNGIZIYJB-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCC(O)C(O)=O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCC(O)C(O)=O GHTNSXNGIZIYJB-UHFFFAOYSA-N 0.000 claims 1
- MGQKIZFIOMOWMD-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCCN1CCN(CC1)c1cccc(O)c1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCCN1CCN(CC1)c1cccc(O)c1 MGQKIZFIOMOWMD-UHFFFAOYSA-N 0.000 claims 1
- PXHVWPGAGILTTG-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCCOc1ccccc1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCCOc1ccccc1 PXHVWPGAGILTTG-UHFFFAOYSA-N 0.000 claims 1
- WNARALDDNLKHFU-MHZLTWQESA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCC[C@H](NC(C)=O)C(O)=O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCC[C@H](NC(C)=O)C(O)=O WNARALDDNLKHFU-MHZLTWQESA-N 0.000 claims 1
- CFFIILWPZHKSCO-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCN1CCN(CC1)C(=O)OC(C)(C)C Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCN1CCN(CC1)C(=O)OC(C)(C)C CFFIILWPZHKSCO-UHFFFAOYSA-N 0.000 claims 1
- SWMNFNVUAKGATC-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCN1CCN(CC1)c1ccccc1OC Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCN1CCN(CC1)c1ccccc1OC SWMNFNVUAKGATC-UHFFFAOYSA-N 0.000 claims 1
- JOHCBQBSUVPKAW-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCOCCOCCN Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCOCCOCCN JOHCBQBSUVPKAW-UHFFFAOYSA-N 0.000 claims 1
- OUCOGLNFTKCDMI-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCOCCOCCO Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCOCCOCCO OUCOGLNFTKCDMI-UHFFFAOYSA-N 0.000 claims 1
- PEYVGLXZBYCPLJ-UHFFFAOYSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCOCc1ccccc1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCOCc1ccccc1 PEYVGLXZBYCPLJ-UHFFFAOYSA-N 0.000 claims 1
- NNZVWHMFBUDHRL-OAQYLSRUSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC[C@@H](O)CO Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC[C@@H](O)CO NNZVWHMFBUDHRL-OAQYLSRUSA-N 0.000 claims 1
- WMWOLWGPDHWGGI-OAQYLSRUSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC[C@H](O)CC(O)=O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC[C@H](O)CC(O)=O WMWOLWGPDHWGGI-OAQYLSRUSA-N 0.000 claims 1
- NNZVWHMFBUDHRL-NRFANRHFSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC[C@H](O)CO Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNC[C@H](O)CO NNZVWHMFBUDHRL-NRFANRHFSA-N 0.000 claims 1
- MWIRGLMFWXSACP-SANMLTNESA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@@H](CO)C(C)C Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@@H](CO)C(C)C MWIRGLMFWXSACP-SANMLTNESA-N 0.000 claims 1
- JVYRNZHCZWYZPD-SANMLTNESA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@@H](CO)C1CC1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@@H](CO)C1CC1 JVYRNZHCZWYZPD-SANMLTNESA-N 0.000 claims 1
- RKUORYVPLXYDFJ-XMMPIXPASA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@@H](CO)CC(C)C Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@@H](CO)CC(C)C RKUORYVPLXYDFJ-XMMPIXPASA-N 0.000 claims 1
- VHIHIYBGLOLLDB-CLOONOSVSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@@H](CO)[C@@H](C)O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@@H](CO)[C@@H](C)O VHIHIYBGLOLLDB-CLOONOSVSA-N 0.000 claims 1
- LRRMSBQHICMFIV-GOSISDBHSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@H](C)CO Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@H](C)CO LRRMSBQHICMFIV-GOSISDBHSA-N 0.000 claims 1
- MWIRGLMFWXSACP-AREMUKBSSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@H](CO)C(C)C Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@H](CO)C(C)C MWIRGLMFWXSACP-AREMUKBSSA-N 0.000 claims 1
- OTXLGVRXIVTOLT-GDLZYMKVSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@H](CO)C1CCCCC1 Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@H](CO)C1CCCCC1 OTXLGVRXIVTOLT-GDLZYMKVSA-N 0.000 claims 1
- VHIHIYBGLOLLDB-UQBPGWFLSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@H](CO)[C@H](C)O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@H](CO)[C@H](C)O VHIHIYBGLOLLDB-UQBPGWFLSA-N 0.000 claims 1
- OPKHCRVDVMEODN-DQEYMECFSA-N COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@H]1COC[C@@H]1O Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN[C@H]1COC[C@@H]1O OPKHCRVDVMEODN-DQEYMECFSA-N 0.000 claims 1
- JEDPSOYOYVELLZ-UHFFFAOYSA-N COc1nc(OCc2cccc(c2C)-c2ccccc2)ccc1CNCCNC(C)=O Chemical compound COc1nc(OCc2cccc(c2C)-c2ccccc2)ccc1CNCCNC(C)=O JEDPSOYOYVELLZ-UHFFFAOYSA-N 0.000 claims 1
- NOWGSSVVPIBQKA-MZNJEOGPSA-N C[C@@H](O)[C@@H](NCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(Cl)c1)C(O)=O Chemical compound C[C@@H](O)[C@@H](NCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(Cl)c1)C(O)=O NOWGSSVVPIBQKA-MZNJEOGPSA-N 0.000 claims 1
- USVJTTKELNGEFF-KRWDZBQOSA-N C[C@H](NCc1ccc(OCc2cccc(c2C)-c2ccccc2)nc1)C(O)=O Chemical compound C[C@H](NCc1ccc(OCc2cccc(c2C)-c2ccccc2)nc1)C(O)=O USVJTTKELNGEFF-KRWDZBQOSA-N 0.000 claims 1
- NOWGSSVVPIBQKA-BXKMTCNYSA-N C[C@H](O)[C@@H](NCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(Cl)c1)C(O)=O Chemical compound C[C@H](O)[C@@H](NCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(Cl)c1)C(O)=O NOWGSSVVPIBQKA-BXKMTCNYSA-N 0.000 claims 1
- NOWGSSVVPIBQKA-XDHUDOTRSA-N C[C@H](O)[C@H](NCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(Cl)c1)C(O)=O Chemical compound C[C@H](O)[C@H](NCc1ccc(OCc2cccc(c2C)-c2ccccc2)c(Cl)c1)C(O)=O NOWGSSVVPIBQKA-XDHUDOTRSA-N 0.000 claims 1
- JICCJBHDBUCHOF-UHFFFAOYSA-N Cc1c(COc2ccc(CN3CCC(O)CC3)cn2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CN3CCC(O)CC3)cn2)cccc1-c1ccccc1 JICCJBHDBUCHOF-UHFFFAOYSA-N 0.000 claims 1
- SSGIGFXOTXBIPP-UHFFFAOYSA-N Cc1c(COc2ccc(CN3CCCC(C3)C(O)=O)cn2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CN3CCCC(C3)C(O)=O)cn2)cccc1-c1ccccc1 SSGIGFXOTXBIPP-UHFFFAOYSA-N 0.000 claims 1
- ZXAATNQIZOFNLF-UHFFFAOYSA-N Cc1c(COc2ccc(CN3CCCC3)cn2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CN3CCCC3)cn2)cccc1-c1ccccc1 ZXAATNQIZOFNLF-UHFFFAOYSA-N 0.000 claims 1
- UDVVLOMZVSOUAM-UHFFFAOYSA-N Cc1c(COc2ccc(CN3CCCCC3C(O)=O)cn2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CN3CCCCC3C(O)=O)cn2)cccc1-c1ccccc1 UDVVLOMZVSOUAM-UHFFFAOYSA-N 0.000 claims 1
- XXYDHIIDTLWPFT-VWLOTQADSA-N Cc1c(COc2ccc(CN3CCCC[C@H]3C(O)=O)cc2C(F)(F)F)cccc1-c1ccc2OCCOc2c1 Chemical compound Cc1c(COc2ccc(CN3CCCC[C@H]3C(O)=O)cc2C(F)(F)F)cccc1-c1ccc2OCCOc2c1 XXYDHIIDTLWPFT-VWLOTQADSA-N 0.000 claims 1
- WZMGGUAUPLVMPY-QHCPKHFHSA-N Cc1c(COc2ccc(CN3CCC[C@H]3CO)cn2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CN3CCC[C@H]3CO)cn2)cccc1-c1ccccc1 WZMGGUAUPLVMPY-QHCPKHFHSA-N 0.000 claims 1
- RYXUHXJUIBOETL-UHFFFAOYSA-N Cc1c(COc2ccc(CNC3CCC(O)CC3)cn2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CNC3CCC(O)CC3)cn2)cccc1-c1ccccc1 RYXUHXJUIBOETL-UHFFFAOYSA-N 0.000 claims 1
- GIZCZRKYQADVIK-UHFFFAOYSA-N Cc1c(COc2ccc(CNC3CCC3)cn2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CNC3CCC3)cn2)cccc1-c1ccccc1 GIZCZRKYQADVIK-UHFFFAOYSA-N 0.000 claims 1
- AAWOJJXSGBUHTG-UHFFFAOYSA-N Cc1c(COc2ccc(CNC3CCCC3)cn2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CNC3CCCC3)cn2)cccc1-c1ccccc1 AAWOJJXSGBUHTG-UHFFFAOYSA-N 0.000 claims 1
- CFNHHYMSHMXMOX-UHFFFAOYSA-N Cc1c(COc2ccc(CNCCC(N)=O)cn2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CNCCC(N)=O)cn2)cccc1-c1ccccc1 CFNHHYMSHMXMOX-UHFFFAOYSA-N 0.000 claims 1
- YAIMPABYXBNRID-UHFFFAOYSA-N Cc1c(COc2ccc(CNCCCN3CCCC3=O)cn2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CNCCCN3CCCC3=O)cn2)cccc1-c1ccccc1 YAIMPABYXBNRID-UHFFFAOYSA-N 0.000 claims 1
- LGQGKOFPLMUHLN-UHFFFAOYSA-N Cc1c(COc2ccc(CNCCO)cn2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CNCCO)cn2)cccc1-c1ccccc1 LGQGKOFPLMUHLN-UHFFFAOYSA-N 0.000 claims 1
- ZVTRRWCFOKYGKX-UHFFFAOYSA-N Cc1c(COc2ccc(CNCCO)nc2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CNCCO)nc2)cccc1-c1ccccc1 ZVTRRWCFOKYGKX-UHFFFAOYSA-N 0.000 claims 1
- GYHIFFSNTRFUJT-UHFFFAOYSA-N Cc1c(COc2ccc(CNCCO)s2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CNCCO)s2)cccc1-c1ccccc1 GYHIFFSNTRFUJT-UHFFFAOYSA-N 0.000 claims 1
- SICPIRDFYMJNER-NRFANRHFSA-N Cc1c(COc2ccc(CNC[C@@H](O)CC(O)=O)nc2)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CNC[C@@H](O)CC(O)=O)nc2)cccc1-c1ccccc1 SICPIRDFYMJNER-NRFANRHFSA-N 0.000 claims 1
- KPSVKGKVOMDLMS-SSEXGKCCSA-N Cc1cc(CN2CCC[C@]2(CC=C)C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 Chemical compound Cc1cc(CN2CCC[C@]2(CC=C)C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1 KPSVKGKVOMDLMS-SSEXGKCCSA-N 0.000 claims 1
- OBGIWFZKATUROZ-UHFFFAOYSA-N Cc1cc(CNCC2CC(=O)N2)ccc1OCc1cccc(c1C)-c1ccccc1 Chemical compound Cc1cc(CNCC2CC(=O)N2)ccc1OCc1cccc(c1C)-c1ccccc1 OBGIWFZKATUROZ-UHFFFAOYSA-N 0.000 claims 1
- PGANARHJTRHDSQ-NRFANRHFSA-N ClC=1C=C(C=CC1OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)CNC[C@H](CC(=O)O)O Chemical compound ClC=1C=C(C=CC1OCC1=C(C(=CC=C1)C1=CC=CC=C1)C)CNC[C@H](CC(=O)O)O PGANARHJTRHDSQ-NRFANRHFSA-N 0.000 claims 1
- OYXRERUYWOJCDX-UHFFFAOYSA-N FC1=C(C=C(C=C1)OCCOC)C=1C(=C(C=CC=1)COC1=CC(=C(C(=C1)OC)CNC(CN1CCN(CC1)C)(C)C)OC)C Chemical compound FC1=C(C=C(C=C1)OCCOC)C=1C(=C(C=CC=1)COC1=CC(=C(C(=C1)OC)CNC(CN1CCN(CC1)C)(C)C)OC)C OYXRERUYWOJCDX-UHFFFAOYSA-N 0.000 claims 1
- XTAJWTVMGCFGRZ-UHFFFAOYSA-N N-[2-[[3-[[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methoxy]-4-(trifluoromethyl)phenyl]methylamino]ethyl]acetamide Chemical compound C1(C=2C(C)=C(COC3=C(C(F)(F)F)C=CC(CNCCNC(=O)C)=C3)C=CC=2)=CC=2OCCOC=2C=C1 XTAJWTVMGCFGRZ-UHFFFAOYSA-N 0.000 claims 1
- UGMDKQKZCHHEKB-UHFFFAOYSA-N N-[2-[[4-[(2-methyl-3-phenylphenyl)methoxy]-2,3-dihydro-1H-inden-1-yl]amino]ethyl]acetamide Chemical compound CC(=O)NCCNC1CCc2c1cccc2OCc1cccc(c1C)-c1ccccc1 UGMDKQKZCHHEKB-UHFFFAOYSA-N 0.000 claims 1
- HUDCMLVCJUTNQL-UHFFFAOYSA-N N-[2-[[4-[[3-(3-ethoxyphenyl)-2-methylphenyl]methoxy]-2,6-dimethoxyphenyl]methylamino]ethyl]acetamide Chemical compound C(C)OC=1C=C(C=CC=1)C=1C(=C(C=CC=1)COC1=CC(=C(C(=C1)OC)CNCCNC(C)=O)OC)C HUDCMLVCJUTNQL-UHFFFAOYSA-N 0.000 claims 1
- OLDRYSNASSVDEG-UHFFFAOYSA-N N-[2-[[6-[(2-methyl-3-phenylphenyl)methoxy]pyridin-3-yl]methylamino]ethyl]acetamide Chemical compound CC1=C(C=CC=C1C1=CC=CC=C1)COC1=CC=C(C=N1)CNCCNC(C)=O OLDRYSNASSVDEG-UHFFFAOYSA-N 0.000 claims 1
- PHDDLHUMRHBWAM-UHFFFAOYSA-N N-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]-2-(1,1-dioxo-1,4-thiazinan-4-yl)ethanamine Chemical compound COC1=CC(OCC2=C(C)C(=CC=C2)C2=CC=CC=C2)=CC(OC)=C1CNCCN1CCS(=O)(=O)CC1 PHDDLHUMRHBWAM-UHFFFAOYSA-N 0.000 claims 1
- RXMHMSRAKLMRGR-UHFFFAOYSA-N N-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]-3-(4-methylpiperazin-1-yl)propan-1-amine Chemical compound COC1=CC(OCC2=C(C)C(=CC=C2)C2=CC=CC=C2)=CC(OC)=C1CNCCCN1CCN(C)CC1 RXMHMSRAKLMRGR-UHFFFAOYSA-N 0.000 claims 1
- YJJMLDZYDIHRJF-UHFFFAOYSA-N N-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]-3-imidazol-1-ylpropan-1-amine Chemical compound COC1=CC(OCC2=C(C)C(=CC=C2)C2=CC=CC=C2)=CC(OC)=C1CNCCCN1C=CN=C1 YJJMLDZYDIHRJF-UHFFFAOYSA-N 0.000 claims 1
- UDRCZSWXLQLTRT-UHFFFAOYSA-N N-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]-3-morpholin-4-ylpropan-1-amine Chemical compound COC1=CC(OCC2=C(C)C(=CC=C2)C2=CC=CC=C2)=CC(OC)=C1CNCCCN1CCOCC1 UDRCZSWXLQLTRT-UHFFFAOYSA-N 0.000 claims 1
- CBVOKWYQTMLEPM-UHFFFAOYSA-N N-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]-4-methylthiolan-3-amine Chemical compound COC1=CC(OCC2=C(C)C(=CC=C2)C2=CC=CC=C2)=CC(OC)=C1CNC1CSCC1C CBVOKWYQTMLEPM-UHFFFAOYSA-N 0.000 claims 1
- HPBRGWJOQDUMOA-UHFFFAOYSA-N N-[[2,6-dimethoxy-4-[[2-methyl-3-(3-prop-2-enoxyphenyl)phenyl]methoxy]phenyl]methyl]-2-methyl-1-(4-methylpiperazin-1-yl)propan-2-amine Chemical compound COc1cc(OCc2cccc(c2C)-c2cccc(OCC=C)c2)cc(OC)c1CNC(C)(C)CN1CCN(C)CC1 HPBRGWJOQDUMOA-UHFFFAOYSA-N 0.000 claims 1
- ZZFWZTXEDHHLIK-UHFFFAOYSA-N N-[[4-[[3-(1,3-benzodioxol-5-yl)-2-methylphenyl]methoxy]-2,6-dimethoxyphenyl]methyl]-2-methyl-1-(4-methylpiperazin-1-yl)propan-2-amine Chemical compound O1COC2=C1C=CC(=C2)C=1C(=C(C=CC=1)COC1=CC(=C(C(=C1)OC)CNC(CN1CCN(CC1)C)(C)C)OC)C ZZFWZTXEDHHLIK-UHFFFAOYSA-N 0.000 claims 1
- PQZJBVBUXJOKLY-UHFFFAOYSA-N N-[[4-[[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methoxy]-2,6-dimethoxyphenyl]methyl]-2-methyl-1-(4-methylpiperazin-1-yl)propan-2-amine Chemical compound COc1cc(OCc2cccc(c2C)-c2ccc3OCCOc3c2)cc(OC)c1CNC(C)(C)CN1CCN(C)CC1 PQZJBVBUXJOKLY-UHFFFAOYSA-N 0.000 claims 1
- PUKRVBFSODQFHJ-UHFFFAOYSA-N N1(CCC1)CC=1C=CC(=NC1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C Chemical compound N1(CCC1)CC=1C=CC(=NC1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)C PUKRVBFSODQFHJ-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- NJNHXAIEMSPCHN-UHFFFAOYSA-N O1CCOC2=C1C=CC(=C2)C=1C(=C(C=CC=1)COC1=CC(=C(C(=C1)OC)CNCCNC(C)=O)OC)C Chemical compound O1CCOC2=C1C=CC(=C2)C=1C(=C(C=CC=1)COC1=CC(=C(C(=C1)OC)CNCCNC(C)=O)OC)C NJNHXAIEMSPCHN-UHFFFAOYSA-N 0.000 claims 1
- YKYUYSHZIOQSPA-UHFFFAOYSA-N OCCNCC1=C(C=C(OCC=2C(=C(C=CC=2)C=2C=C(C=CC=2)O)C)C=C1OC)OC Chemical compound OCCNCC1=C(C=C(OCC=2C(=C(C=CC=2)C=2C=C(C=CC=2)O)C)C=C1OC)OC YKYUYSHZIOQSPA-UHFFFAOYSA-N 0.000 claims 1
- XKPLUFKYCZERKI-QFIPXVFZSA-N OC[C@H]1N(CCC1)CC1=C(C=C(OCC2=C(C#N)C(=CC=C2)C2=CC=CC=C2)C=C1OC)OC Chemical compound OC[C@H]1N(CCC1)CC1=C(C=C(OCC2=C(C#N)C(=CC=C2)C2=CC=CC=C2)C=C1OC)OC XKPLUFKYCZERKI-QFIPXVFZSA-N 0.000 claims 1
- VYPCCNKMGFVEHQ-UHFFFAOYSA-N [1-[[5-[(2-methyl-3-phenylphenyl)methoxy]pyridin-2-yl]methylamino]cyclopentyl]methanol Chemical compound CC1=C(C=CC=C1C1=CC=CC=C1)COC=1C=CC(=NC1)CNC1(CCCC1)CO VYPCCNKMGFVEHQ-UHFFFAOYSA-N 0.000 claims 1
- WAEJPUPLURAWGG-UHFFFAOYSA-N [1-[[6-[(2-methyl-3-phenylphenyl)methoxy]pyridin-3-yl]methylamino]cyclopentyl]methanol Chemical compound CC1=C(C=CC=C1C1=CC=CC=C1)COC1=CC=C(C=N1)CNC1(CCCC1)CO WAEJPUPLURAWGG-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- BKRRXUDJPUGALD-UHFFFAOYSA-N benzyl N-[2-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]ethyl]carbamate Chemical compound COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CNCCNC(=O)OCc1ccccc1 BKRRXUDJPUGALD-UHFFFAOYSA-N 0.000 claims 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361873398P | 2013-09-04 | 2013-09-04 | |
| US61/873,398 | 2013-09-04 | ||
| PCT/US2014/053695 WO2015034820A1 (en) | 2013-09-04 | 2014-09-02 | Compounds useful as immunomodulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016536333A JP2016536333A (ja) | 2016-11-24 |
| JP2016536333A5 true JP2016536333A5 (enExample) | 2017-10-05 |
| JP6417419B2 JP6417419B2 (ja) | 2018-11-07 |
Family
ID=51539384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540311A Expired - Fee Related JP6417419B2 (ja) | 2013-09-04 | 2014-09-02 | 免疫調節剤として有用な化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9872852B2 (enExample) |
| EP (1) | EP3041822B1 (enExample) |
| JP (1) | JP6417419B2 (enExample) |
| KR (1) | KR102276644B1 (enExample) |
| CN (1) | CN105705489B (enExample) |
| AU (1) | AU2014315457B2 (enExample) |
| BR (1) | BR112016004194A8 (enExample) |
| CA (1) | CA2923184A1 (enExample) |
| CL (2) | CL2016000508A1 (enExample) |
| EA (1) | EA029901B1 (enExample) |
| ES (1) | ES2642074T3 (enExample) |
| IL (1) | IL244346B (enExample) |
| MX (1) | MX2016002544A (enExample) |
| PE (1) | PE20160432A1 (enExample) |
| SG (1) | SG11201601225RA (enExample) |
| WO (1) | WO2015034820A1 (enExample) |
Families Citing this family (250)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2928474B1 (en) | 2012-12-07 | 2018-11-14 | ChemoCentryx, Inc. | Diazole lactams |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| AU2016263579B2 (en) | 2015-05-21 | 2020-12-03 | Chemocentryx, Inc. | CCR2 modulators |
| WO2016198691A1 (en) | 2015-06-11 | 2016-12-15 | Basilea Pharmaceutica Ag | Efflux-pump inhibitors and therapeutic uses thereof |
| US10745382B2 (en) * | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HUE060680T2 (hu) | 2015-11-19 | 2023-04-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| MA44075A (fr) | 2015-12-17 | 2021-05-19 | Incyte Corp | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
| ES2844374T3 (es) | 2015-12-22 | 2021-07-22 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3190103A1 (en) | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
| US10568870B2 (en) | 2016-04-07 | 2020-02-25 | Chemocentryx, Inc. | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors |
| ES2906460T3 (es) * | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2017202274A1 (zh) * | 2016-05-23 | 2017-11-30 | 中国医学科学院药物研究所 | 烟醇醚类衍生物、及其制法和药物组合物与用途 |
| WO2017205464A1 (en) * | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HUE060256T2 (hu) * | 2016-06-20 | 2023-02-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
| JP7090037B2 (ja) * | 2016-06-23 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | 新規な［１，２，３］トリアゾロ［４，５－ｄ］ピリミジン誘導体 |
| ES2979332T3 (es) * | 2016-06-27 | 2024-09-25 | Chemocentryx Inc | Compuestos inmunomoduladores |
| AU2017294231B2 (en) * | 2016-07-05 | 2021-09-09 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof |
| SG11201900077QA (en) * | 2016-07-08 | 2019-02-27 | Bristol Myers Squibb Co | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2905755T3 (es) | 2016-07-28 | 2022-04-12 | Idorsia Pharmaceuticals Ltd | Derivados de piperidina |
| AU2017305399A1 (en) * | 2016-08-03 | 2019-01-31 | Arising International, Inc. | Symmetric or semi-symmetric compounds useful as immunomodulators |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| US10144706B2 (en) * | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| US12298309B2 (en) | 2016-09-06 | 2025-05-13 | Incelldx, Inc. | Methods of assaying neoplastic and neoplasia-related cells and uses thereof |
| US11726089B2 (en) | 2016-09-06 | 2023-08-15 | Incelldx, Inc. | Methods of assaying neoplastic and neoplasia-related cells and uses thereof |
| CA3036278A1 (en) * | 2016-09-06 | 2018-03-15 | Incelldx, Inc. | Methods of detecting per cell pd-l1 expression and uses thereof |
| CN117402852A (zh) | 2016-10-14 | 2024-01-16 | 精密生物科学公司 | 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶 |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| CN110072860B (zh) * | 2016-12-20 | 2022-09-02 | 百时美施贵宝公司 | 可用作免疫调节剂的化合物 |
| ES2899402T3 (es) * | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| UA127785C2 (uk) | 2016-12-22 | 2024-01-03 | Інсайт Корпорейшн | ПОХІДНІ ТЕТРАГІДРОІМІДАЗО[4,5-c]ПІРИДИНУ, ЯКІ ВИКЛИКАЮТЬ ІНТЕРНАЛІЗАЦІЮ PD-L1 |
| US20180177784A1 (en) * | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| GEP20227428B (en) | 2016-12-22 | 2022-10-25 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| US20190336533A1 (en) | 2016-12-28 | 2019-11-07 | Green Cross Lab Cell Corporation | Chimeric antigen receptor and natural killer cells expressing same |
| CN108250159B (zh) * | 2016-12-29 | 2023-07-11 | 深圳微芯生物科技股份有限公司 | 脲类化合物、其制备方法及其应用 |
| EP3565842A1 (en) | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| US11046675B2 (en) | 2017-03-27 | 2021-06-29 | Bristol-Myers Squibb Company | Substituted isoquionline derivatives as immunomudulators |
| JOP20180040A1 (ar) * | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2018200571A1 (en) | 2017-04-25 | 2018-11-01 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1h-indene analogs and methods using same |
| PE20191811A1 (es) | 2017-05-18 | 2019-12-26 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| SG11201908660RA (en) | 2017-05-18 | 2019-10-30 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| CA3063632A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| AR111874A1 (es) | 2017-05-18 | 2019-08-28 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
| CA3060597A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as pge2 receptor modulators |
| WO2018223004A1 (en) | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 |
| CA3065929A1 (en) | 2017-06-01 | 2018-12-06 | Michael Wayne SAVILLE | Bispecific antibodies that bind cd123 and cd3 |
| WO2019008156A1 (en) | 2017-07-07 | 2019-01-10 | Rijksuniversiteit Groningen | INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1 |
| WO2019008152A1 (en) | 2017-07-07 | 2019-01-10 | Rijksuniversiteit Groningen | 3-CYANOTHIOPHENE DERIVATIVES AS INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1 |
| WO2019008154A1 (en) | 2017-07-07 | 2019-01-10 | Rijksuniversiteit Groningen | 3- (AZOLYLMETHOXY) BIPHENYL DERIVATIVES AS INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1 |
| MA49701A (fr) | 2017-07-28 | 2020-06-03 | Chemocentryx Inc | Composés immunomodulateurs |
| JP7198269B2 (ja) | 2017-08-08 | 2022-12-28 | ケモセントリックス，インコーポレイティド | 大員環免疫調節剤 |
| JP7110325B2 (ja) | 2017-08-17 | 2022-08-01 | イドーシア ファーマシューティカルズ リミテッド | インドールアミン ２，３－ジオキシゲナーゼ及び／又はトリプトファン ２，３－ジオキシゲナーゼの阻害剤 |
| EP3669872A4 (en) * | 2017-08-18 | 2021-05-05 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | FORMYL PYRIDINE DERIVATIVE WITH PD-L1 INHIBITORING EFFECT, MANUFACTURING METHOD FOR IT AND USE THEREOF |
| SG11202002032SA (en) | 2017-09-22 | 2020-04-29 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| JP7453139B2 (ja) | 2017-09-25 | 2024-03-19 | ケモセントリックス，インコーポレイティド | ケモカイン受容体２（ｃｃｒ２）アンタゴニスト及びｐｄ－１／ｐｄ－ｌ１阻害剤を使用した併用療法 |
| CN109665968B (zh) * | 2017-10-16 | 2022-02-22 | 四川科伦博泰生物医药股份有限公司 | 并环化合物及其制备方法和用途 |
| AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| CN109721527B (zh) * | 2017-10-27 | 2024-03-12 | 广州丹康医药生物有限公司 | 一种新型抗pd-l1化合物、其应用及含其的组合物 |
| KR20200085836A (ko) * | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
| CN111315398A (zh) | 2017-11-10 | 2020-06-19 | 阿尔莫生物科技股份有限公司 | 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法 |
| AU2018363292A1 (en) | 2017-11-13 | 2020-05-21 | Crescendo Biologics Limited | Molecules that bind to CD137 and PSMA |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| AU2018370195B2 (en) | 2017-11-14 | 2022-01-13 | Green Cross Lab Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| AU2018372211B2 (en) | 2017-11-24 | 2023-02-02 | Jubilant Episcribe LLC, | Heterocyclic compounds as PRMT5 inhibitors |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| WO2019120297A1 (zh) * | 2017-12-22 | 2019-06-27 | 上海海雁医药科技有限公司 | 免疫调节剂及其制法与医药上的用途 |
| SG11202005962YA (en) | 2017-12-29 | 2020-07-29 | Guangzhou Maxinovel Pharmaceuticals Co Ltd | Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| WO2019136368A2 (en) | 2018-01-08 | 2019-07-11 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| ES2983284T3 (es) | 2018-01-09 | 2024-10-22 | Shuttle Pharmaceuticals Inc | Inhibidores selectivos de histona deacetilasa para el tratamiento de enfermedades humanas |
| SI3737684T1 (sl) | 2018-01-10 | 2023-01-31 | Idorsia Pharmaceuticals Ltd | Derivati 2,4,6,7-tetrahidro-pirazolo(4,3-D)pirimidin-5-ona in sorodne spojine kot modulatorji receptorja C5A za zdravljenje vaskulitisa in vnetnih bolezni |
| US20200405696A1 (en) | 2018-01-15 | 2020-12-31 | Idorsia Pharmaceuticals Ltd | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase |
| US11739070B2 (en) | 2018-01-19 | 2023-08-29 | Idorsia Pharmaceuticals Ltd. | C5A receptor modulators |
| US11685729B2 (en) | 2018-01-19 | 2023-06-27 | Idorsia Pharmaceuticals Ltd. | C5a receptor modulators |
| EP3743425B1 (en) | 2018-01-23 | 2024-11-27 | Bristol-Myers Squibb Company | 2,8-diacyl-2,8-diazaspiro[5.5]undecane compounds useful as immunomodulators |
| EP3743422B1 (en) | 2018-01-26 | 2024-03-13 | Idorsia Pharmaceuticals Ltd | Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide |
| CN110092740B (zh) * | 2018-01-29 | 2022-10-14 | 广州丹康医药生物有限公司 | 一种稠环化合物及其应用 |
| CN110092779B (zh) * | 2018-01-29 | 2022-07-12 | 广州丹康医药生物有限公司 | 一种取代的苯基化合物及其应用 |
| EP3750887B1 (en) * | 2018-02-05 | 2025-05-28 | Abbisko Therapeutics Co., Ltd. | Biaryl derivatives and their pharmaceutical application for the treatment of pd-1/pd-l1 signal pathway-mediated diseases |
| UA126458C2 (uk) * | 2018-02-13 | 2022-10-05 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| WO2019165043A2 (en) | 2018-02-22 | 2019-08-29 | Chemocentryx, Inc. | Indane-amines as pd-l1 antagonists |
| ES2962605T3 (es) | 2018-02-26 | 2024-03-20 | Gilead Sciences Inc | Compuestos de pirrolizina sustituidos como inhibidores de la replicación del VHB |
| EP3759093B1 (en) | 2018-03-01 | 2022-11-30 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| CN110240587B (zh) * | 2018-03-08 | 2022-01-04 | 中国科学院上海药物研究所 | 一类芳基二氟苄基醚类化合物、制备方法及用途 |
| AU2019234185B2 (en) * | 2018-03-13 | 2024-08-01 | Jubilant Prodel LLC. | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
| WO2019174533A1 (zh) * | 2018-03-13 | 2019-09-19 | 广东东阳光药业有限公司 | Pd-1/pd-l1类小分子抑制剂及其在药物中的应用 |
| FI4212529T3 (fi) | 2018-03-30 | 2025-04-23 | Incyte Corp | Heterosyklisiä yhdisteitä immunomodulaattoreina |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| SMT202300127T1 (it) | 2018-05-11 | 2023-05-12 | Incyte Corp | Derivati di tetraidro-imidazo[4,5-c]piridina come immunomodulatori di pd-l1 |
| SG11202011651SA (en) | 2018-05-31 | 2020-12-30 | Ono Pharmaceutical Co | Biomarkers for determining the effectiveness of immune checkpoint inhibitors |
| US20210205449A1 (en) | 2018-06-01 | 2021-07-08 | Novartis Ag | Dosing of a bispecific antibody that bind cd123 and cd3 |
| US20210347842A1 (en) | 2018-06-19 | 2021-11-11 | Eli Lilly And Company | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| CN109305934A (zh) * | 2018-08-07 | 2019-02-05 | 成都海博锐药业有限公司 | 苯醚类衍生物及可药用盐、医药上的用途 |
| CN111892516A (zh) * | 2018-08-08 | 2020-11-06 | 中国人民解放军总医院 | 抗肿瘤化合物 |
| CN110872275A (zh) * | 2018-08-31 | 2020-03-10 | 深圳微芯生物科技股份有限公司 | 作为免疫调节剂的联苯化合物及其用途 |
| TW202446772A (zh) | 2018-10-11 | 2024-12-01 | 日商小野藥品工業股份有限公司 | Ｓｔｉｎｇ促效化合物 |
| AU2019366355B2 (en) * | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| JP7273172B2 (ja) | 2018-10-31 | 2023-05-12 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｐｋ１阻害活性を有する置換６－アザベンゾイミダゾール化合物 |
| BR112021008255A2 (pt) | 2018-10-31 | 2021-08-03 | Gilead Sciences, Inc. | compostos de 6-azabenzimidazol substituídos como inibidores de hpk1 |
| JP2022513592A (ja) | 2018-11-02 | 2022-02-09 | シャンハイ マキシノベル ファーマシューティカルズ カンパニー リミテッド | ビフェニル系化合物、その中間体、製造方法、医薬組成物及び使用 |
| CN109456284A (zh) * | 2018-11-13 | 2019-03-12 | 南方医科大学 | 一种含取代联苯的查尔酮及其应用 |
| CN109438263A (zh) * | 2018-11-28 | 2019-03-08 | 南方医科大学 | 一种含取代联苯的萘及其应用 |
| US12516382B2 (en) | 2018-12-07 | 2026-01-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of determining risk for skin cancer development and skin cancer therapeutic prevention by measuring PD-1/PD-L1 signaling pathway members |
| CN109503546A (zh) * | 2019-01-10 | 2019-03-22 | 南方医科大学 | 一种间苯二酚二苯甲醚及其应用 |
| CN113454458A (zh) | 2019-02-05 | 2021-09-28 | 文塔纳医疗系统公司 | 用于评估iv期结直肠癌中免疫细胞浸润的方法和系统 |
| TW202045487A (zh) | 2019-02-21 | 2020-12-16 | 大陸商杭州阿諾生物醫藥科技有限公司 | Pd-l1拮抗劑化合物 |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| US12318403B2 (en) | 2019-03-07 | 2025-06-03 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′-cyclic dinucleotides and prodrugs thereof |
| SG11202110388VA (en) | 2019-03-22 | 2021-10-28 | Guangzhou Maxinovel Pharmaceuticals Co Ltd | Small-molecule inhibitor of pd-1/pd-l1, pharmaceutical composition thereof with pd-l1 antibody, and application of same |
| JP2022527177A (ja) | 2019-03-28 | 2022-05-31 | ブリストル－マイヤーズ スクイブ カンパニー | 腫瘍を処置する方法 |
| JP2022526960A (ja) | 2019-03-28 | 2022-05-27 | ブリストル－マイヤーズ スクイブ カンパニー | 腫瘍を処置する方法 |
| CN111747927B (zh) * | 2019-03-29 | 2023-08-18 | 广州丹康医药生物有限公司 | 作为免疫调节剂的化合物及其应用 |
| WO2020204714A1 (en) | 2019-04-02 | 2020-10-08 | Immunetune B.V. | Immune-stimulatory compositions and use thereof |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| WO2020225077A1 (en) | 2019-05-03 | 2020-11-12 | Idorsia Pharmaceuticals Ltd | Pyrimido[4,5-b]indol derivatives as pdhk1 inhibitors |
| KR20210153665A (ko) * | 2019-05-10 | 2021-12-17 | 상하이 하이옌 파마슈티컬 테크놀로지 컴퍼니, 리미티드 | 치환된 페닐프로펜일피리딘 유도체, 이의 제조 방법 및 이의 의약 용도 |
| BR112021022659A2 (pt) | 2019-05-15 | 2022-03-29 | Chemocentryx Inc | Compostos triarílicos para o tratamento de doenças pd-l1 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| WO2020244518A1 (zh) * | 2019-06-04 | 2020-12-10 | 中国科学院上海药物研究所 | 一种具有苄氧基芳环结构的化合物，其制备方法和用途 |
| JP7768770B2 (ja) * | 2019-06-07 | 2025-11-12 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Ｐｄｌ１チェックポイント阻害剤としての複素環式免疫調節剤 |
| CN113557236B (zh) * | 2019-06-10 | 2022-05-10 | 中国科学院广州生物医药与健康研究院 | 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物 |
| US20220339285A1 (en) | 2019-06-12 | 2022-10-27 | Technical University Of Denmark | Dissacharide formulations for controlled drug release |
| BR112021023750A2 (pt) | 2019-06-20 | 2022-01-11 | Chemocentryx Inc | Compostos para tratamento de doenças pd-l1 |
| CN112121169B (zh) * | 2019-06-24 | 2023-10-24 | 广州再极医药科技有限公司 | 用于治疗具有高间质压力的肿瘤受试者的癌症的小分子抑制剂 |
| PH12022550034A1 (en) | 2019-07-09 | 2022-11-21 | Idorsia Pharmaceuticals Ltd | Pharmaceutical composition comprising a tetrahydropyrazolopyrimidinone compound |
| KR102890201B1 (ko) | 2019-07-10 | 2025-11-24 | 케모센트릭스, 인크. | Pd-l1 억제제로서의 인단 |
| CA3146406A1 (en) | 2019-07-11 | 2021-01-14 | Idorsia Pharmaceuticals Ltd | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase |
| WO2021025554A1 (en) | 2019-08-02 | 2021-02-11 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination comprising an activator of the glucocorticoid receptor and an inhibitor of ifg-1 signaling for carcinoma treatment |
| KR20220041099A (ko) | 2019-08-05 | 2022-03-31 | 오노 야꾸힝 고교 가부시키가이샤 | 면역 체크포인트 저해약의 유효성 판정 바이오마커 |
| US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN111909108B (zh) * | 2019-09-02 | 2023-05-02 | 中国药科大学 | 联苯类化合物及其制备方法和医药用途 |
| AU2020350795A1 (en) | 2019-09-22 | 2022-03-31 | Bristol-Myers Squibb Company | Quantitative spatial profiling for LAG-3 antagonist therapy |
| CN112574183B (zh) * | 2019-09-29 | 2022-07-08 | 南京华威医药科技集团有限公司 | 一种pd-1抑制剂及其制备方法和用途 |
| AU2020357529A1 (en) | 2019-09-30 | 2022-05-19 | Medshine Discovery Inc. | Compound as small molecule inhibitor PD-1/PD-L1 and application thereof |
| KR20220075382A (ko) | 2019-09-30 | 2022-06-08 | 인사이트 코포레이션 | 면역조절제로서의 피리도[3,2-d]피리미딘 화합물 |
| IL315295A (en) | 2019-09-30 | 2024-10-01 | Gilead Sciences Inc | Hbv vaccines and methods treating hbv |
| KR20220079893A (ko) * | 2019-10-04 | 2022-06-14 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제로서 유용한 화합물 |
| MX2022004487A (es) | 2019-10-16 | 2022-05-06 | Corcept Therapeutics Inc | Metodo para normalizar el indice de neutrofilos a linfocitos en pacientes con cancer con un antagonista del receptor de glucocorticoide selectivo. |
| EP4045036A4 (en) | 2019-10-16 | 2023-11-15 | ChemoCentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
| CR20220216A (es) | 2019-10-16 | 2023-01-09 | Chemocentryx Inc | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 |
| EP4048273A1 (en) | 2019-10-21 | 2022-08-31 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Novel drug combinations for treatment of a carcinoma |
| US20220411499A1 (en) | 2019-11-08 | 2022-12-29 | Bristol-Myers Squibb Company | LAG-3 Antagonist Therapy for Melanoma |
| KR20220101664A (ko) | 2019-11-11 | 2022-07-19 | 인사이트 코포레이션 | Pd-1/pd-l1 억제제의 염 및 결정질 형태 |
| WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| EP4083032A4 (en) * | 2019-12-26 | 2023-10-25 | Adlai Nortye Biopharma Co., Ltd. | Pd-l1 antagonist compound |
| WO2021136354A1 (zh) | 2020-01-03 | 2021-07-08 | 上海翰森生物医药科技有限公司 | 联苯类衍生物抑制剂、其制备方法和应用 |
| KR102653906B1 (ko) | 2020-01-14 | 2024-04-03 | 신테카인, 인크. | 편향된 il2 뮤테인 방법 및 조성물 |
| CN111187172B (zh) * | 2020-01-20 | 2021-10-29 | 中国药科大学 | 硝基苯醚类化合物、其制备方法和药物组合物与用途 |
| WO2021154750A1 (en) | 2020-01-29 | 2021-08-05 | Corcept Therapeutics Incorporated | TREATMENT OF ADRENOCORTICAL CARCINOMA WITH SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS (SGRMs) AND ANTIBODY CHECKPOINT INHIBITORS |
| WO2021171264A1 (en) | 2020-02-28 | 2021-09-02 | Novartis Ag | Dosing of a bispecific antibody that binds cd123 and cd3 |
| WO2021183370A1 (en) * | 2020-03-11 | 2021-09-16 | Purdue Research Foundation | Compounds with immunomodulatory activity and therapeutic uses thereof |
| JP2023518433A (ja) | 2020-03-20 | 2023-05-01 | ギリアード サイエンシーズ， インコーポレイテッド | ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法 |
| CN111303122A (zh) * | 2020-04-07 | 2020-06-19 | 南方医科大学 | 一种泊马度胺衍生物及其用途 |
| CN111333629B (zh) * | 2020-04-10 | 2021-03-05 | 颜建发 | 苯基-1h-吡唑类衍生物及其在抗肿瘤药物中的应用 |
| JPWO2021206158A1 (enExample) | 2020-04-10 | 2021-10-14 | ||
| US20230151024A1 (en) | 2020-04-10 | 2023-05-18 | Ono Pharmaceutical Co., Ltd. | Sting agonistic compound |
| CN111559981B (zh) * | 2020-04-15 | 2023-08-01 | 杭州庆正鸿科技有限公司 | 一种联苯-嘧啶偶联物及其制备方法和应用 |
| US20230330223A1 (en) | 2020-04-27 | 2023-10-19 | Agendia N.V. | Treatment of her2 negative, mammaprint high risk 2 breast cancer |
| CN113563260A (zh) * | 2020-04-28 | 2021-10-29 | 药康众拓(江苏)医药科技有限公司 | 苯甲酰胺类化合物、制备方法及用途 |
| CN113582971B (zh) * | 2020-04-30 | 2023-10-20 | 北京康辰药业股份有限公司 | 一种小分子免疫抑制剂、其制备方法及其应用 |
| CN113943330A (zh) * | 2020-07-17 | 2022-01-18 | 中国科学院上海药物研究所 | 一类含糖结构化合物、其制备方法、药物组合物和用途 |
| CN114075123B (zh) * | 2020-08-11 | 2023-06-06 | 中国人民解放军军事科学院军事医学研究院 | 苄胺类衍生物及其制备方法与用途 |
| AU2021331476A1 (en) | 2020-08-28 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| TW202214568A (zh) | 2020-09-09 | 2022-04-16 | 大陸商廣州再極醫藥科技有限公司 | 芳香乙烯類化合物、其製備方法、中間體、藥物組合物及其應用 |
| CA3194742A1 (en) | 2020-09-10 | 2022-03-17 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing pd-1 antagonist prodrugs useful in the treatment of cancer and methods thereof |
| JP2023548051A (ja) | 2020-10-23 | 2023-11-15 | ブリストル－マイヤーズ スクイブ カンパニー | 肺がんのためのｌａｇ－３アンタゴニスト療法 |
| IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| CN114507227B (zh) * | 2020-11-17 | 2024-06-21 | 中国医学科学院药物研究所 | 苯并异噻唑类化合物、及其制法和药物组合物与用途 |
| EP4251772A1 (en) | 2020-11-26 | 2023-10-04 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Personalized tumor markers |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| CA3204162A1 (en) | 2021-01-11 | 2022-07-14 | Robert Kastelein | Compositions and methods related to receptor pairing |
| US20240092942A1 (en) | 2021-03-05 | 2024-03-21 | Leadartis, S.L. | Trimeric polypeptides and uses thereof in the treatment of cancer |
| WO2022199578A1 (zh) * | 2021-03-22 | 2022-09-29 | 南京明德新药研发有限公司 | 氟代乙烯基联苯衍生物及其应用 |
| CN113105431B (zh) * | 2021-03-24 | 2022-10-28 | 河北康泰药业有限公司 | 一种蛋白水解靶向嵌合体及其应用 |
| IL307262A (en) | 2021-03-29 | 2023-11-01 | Juno Therapeutics Inc | METHODS FOR DOSAGE AND THERAPY IN COMBINATION OF CHECKPOINT INHIBITOR AND CAR T CELL THERAPY |
| BR112023021790A2 (pt) * | 2021-04-22 | 2023-12-26 | Jubilant Prodel LLC | Composto de fórmula (i); composto selecionado; processo para preparação de compostos de fórmula (i); composição farmacêutica; método para o tratamento e/ou prevenção de uma condição mediada por pd-1/pd-l1 ou um distúrbio proliferativo ou câncer; método para o tratamento ou prevenção de doença ou distúrbio proliferativo ou câncer; uso dos compostos; e; método para o tratamento de câncer |
| CN113135895A (zh) | 2021-04-30 | 2021-07-20 | 中国药科大学 | 一种新型联苯类衍生物及其制备方法与医药用途 |
| JP2024517837A (ja) * | 2021-05-05 | 2024-04-23 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤として有用なラクトンおよびラクタム含有化合物 |
| TW202310852A (zh) | 2021-05-13 | 2023-03-16 | 美商基利科學股份有限公司 | ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合 |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
| CA3222269A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| US12018015B2 (en) * | 2021-06-18 | 2024-06-25 | Aligos Therapeutics, Inc. | Methods and compositions for targeting PD-L1 |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CR20230585A (es) | 2021-06-23 | 2024-02-19 | Gilead Sciences Inc | Compuestos Moduladores de Diacilglicerol Quinasa. |
| IT202100016775A1 (it) * | 2021-06-25 | 2022-12-25 | Univ Degli Studi Milano | Derivati triazinici per il trattamento dei tumori e di disturbi neurodegenerativi |
| JP2024529340A (ja) | 2021-07-14 | 2024-08-06 | シンセカイン インコーポレイテッド | 新生物疾患の細胞療法に使用するための方法および組成物 |
| CN114437051A (zh) * | 2021-09-18 | 2022-05-06 | 药康众拓(江苏)医药科技有限公司 | 一类联苯类化合物、其制备方法和用途 |
| WO2023057548A1 (en) | 2021-10-07 | 2023-04-13 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| TW202325278A (zh) | 2021-10-26 | 2023-07-01 | 瑞士商愛杜西亞製藥有限公司 | Ccr6受體調節劑 |
| KR20240090693A (ko) | 2021-10-28 | 2024-06-21 | 이도르시아 파마슈티컬스 리미티드 | Ccr6 수용체 조절인자 |
| AU2022375806A1 (en) | 2021-10-29 | 2023-12-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| WO2023080788A1 (en) | 2021-11-05 | 2023-05-11 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Tryptophan depletion induces production and presentation of tryptophan to phenylalanine substitutions |
| CN118715214A (zh) | 2021-12-06 | 2024-09-27 | 赫姆霍兹-森德拉姆德雷斯顿-罗森多夫研究中心 | 3-((3-([1,1’-联苯基]-3-基甲氧基)苯氧基)甲基)苄腈衍生物及其用途 |
| MX2024008831A (es) | 2022-01-26 | 2024-07-25 | Bristol Myers Squibb Co | Terapia combinada para carcinoma hepatocelular. |
| CN116768870A (zh) * | 2022-03-08 | 2023-09-19 | 中国科学院上海药物研究所 | 具有苄氧基芳基醚结构的化合物及其制备方法和用途 |
| WO2023192946A1 (en) | 2022-03-31 | 2023-10-05 | Ventana Medical Systems, Inc. | Methods and systems for predicting response to pd-1 axis directed therapeutics in colorectal tumors with deficient mismatch repair |
| CN119731651A (zh) | 2022-04-08 | 2025-03-28 | 百时美施贵宝公司 | 三级淋巴结构的机器学习标识、分类和量化 |
| EP4526470A1 (en) | 2022-05-19 | 2025-03-26 | Agendia N.V. | Prediction of response to immune therapy in breast cancer patients |
| EP4282435A1 (en) | 2022-05-23 | 2023-11-29 | Danmarks Tekniske Universitet | Formulations of active pharmaceutical ingredients and excipients in icells via hydrophobic ion pairing |
| EP4282448A1 (en) | 2022-05-23 | 2023-11-29 | Danmarks Tekniske Universitet | Porous expanding biocompatible scaffolds |
| IL318949A (en) | 2022-08-23 | 2025-04-01 | Ono Pharmaceutical Co | Bispecific antibody |
| CN116283896B (zh) * | 2022-09-07 | 2024-10-29 | 广东晨康生物科技有限公司 | 一种具有pd-l1抑制活性的联苯类化合物及其用途 |
| CN115417870B (zh) * | 2022-09-20 | 2024-02-27 | 中国药科大学 | Pd-l1＆nampt双靶点抑制剂和用途 |
| CN115477609B (zh) * | 2022-09-26 | 2024-03-12 | 浙江师范大学 | 基于疏水标签技术的pd-l1蛋白降解剂及其应用 |
| CN118265699A (zh) * | 2022-10-26 | 2024-06-28 | 西安新通药物研究股份有限公司 | 一种非对称性联苯衍生物及其制备方法与医药用途 |
| JP2025527595A (ja) * | 2022-11-22 | 2025-08-22 | 西安新通薬物研究股▲フン▼有限公司 | 新規二環系ｐｄ－ｌ１阻害剤、その製造方法、及び医薬使用 |
| AR131211A1 (es) | 2022-11-30 | 2025-02-26 | Idorsia Pharmaceuticals Ltd | Derivados de aril- y heteroaril-sulfonamida como moduladores de ccr8 |
| TW202440565A (zh) | 2022-12-06 | 2024-10-16 | 瑞士商愛杜西亞製藥有限公司 | 結晶鹽形式 |
| AU2023409221A1 (en) | 2022-12-21 | 2025-06-12 | Bristol-Myers Squibb Company | Combination therapy for lung cancer |
| WO2024186917A2 (en) * | 2023-03-06 | 2024-09-12 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions for pd-l1 inhibition and methods of use thereof |
| WO2024183756A1 (zh) * | 2023-03-07 | 2024-09-12 | 上海再极医药科技有限公司 | 一种含苯环类化合物及其制备方法和应用 |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| GB202318675D0 (en) | 2023-12-06 | 2024-01-17 | Oncopeptides Ab | Novel polypeptides |
| WO2025159640A1 (en) | 2024-01-24 | 2025-07-31 | Agendia N.V. | Method for assessing a risk of breast cancer recurrence |
| WO2025198469A1 (en) | 2024-03-18 | 2025-09-25 | Agendia N.V. | Prediction of response to immune therapy in triple negative breast cancer patients. |
| CN117986158A (zh) * | 2024-04-03 | 2024-05-07 | 云南大学 | 取代联苯类化合物、制备方法及应用 |
| WO2025229177A1 (en) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of an n-substituted indole derivative |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
| WO2025261989A1 (en) | 2024-06-18 | 2025-12-26 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | 1,2,3-TRIAZOLE DERIVATIVES AS IL4i1 INHIBITORS |
| CN119350185A (zh) * | 2024-10-08 | 2025-01-24 | 聊城大学 | 一种联苯羟肟类衍生物及其制备方法和用途 |
| CN119350297B (zh) * | 2024-12-25 | 2025-04-04 | 浙江大学 | 一种特异性溶酶体靶向嵌合体分子及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994018167A1 (fr) * | 1993-02-01 | 1994-08-18 | Kaken Pharmaceutical Co., Ltd. | Derive de dibenzylamine substitue |
| US6297239B1 (en) * | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| EP1481965B1 (en) * | 2002-02-07 | 2015-07-29 | Hitoshi Endo | Aromatic amino acid derivatives and medicinal compositions |
| JPWO2004007439A1 (ja) | 2002-07-10 | 2005-11-10 | 住友製薬株式会社 | ビアリール誘導体 |
| EP1559422B1 (en) | 2002-11-08 | 2014-04-30 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| US9321730B2 (en) * | 2007-08-21 | 2016-04-26 | The Hong Kong Polytechnic University | Method of making and administering quinoline derivatives as anti-cancer agents |
| TW200932219A (en) | 2007-10-24 | 2009-08-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| WO2010059838A2 (en) * | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects |
| US20130022629A1 (en) * | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
-
2014
- 2014-09-02 US US14/915,782 patent/US9872852B2/en active Active
- 2014-09-02 PE PE2016000338A patent/PE20160432A1/es not_active Application Discontinuation
- 2014-09-02 KR KR1020167008405A patent/KR102276644B1/ko not_active Expired - Fee Related
- 2014-09-02 EA EA201690316A patent/EA029901B1/ru not_active IP Right Cessation
- 2014-09-02 BR BR112016004194A patent/BR112016004194A8/pt not_active Application Discontinuation
- 2014-09-02 MX MX2016002544A patent/MX2016002544A/es unknown
- 2014-09-02 AU AU2014315457A patent/AU2014315457B2/en not_active Ceased
- 2014-09-02 EP EP14766086.4A patent/EP3041822B1/en not_active Not-in-force
- 2014-09-02 JP JP2016540311A patent/JP6417419B2/ja not_active Expired - Fee Related
- 2014-09-02 ES ES14766086.4T patent/ES2642074T3/es active Active
- 2014-09-02 WO PCT/US2014/053695 patent/WO2015034820A1/en not_active Ceased
- 2014-09-02 CN CN201480060895.6A patent/CN105705489B/zh not_active Expired - Fee Related
- 2014-09-02 CA CA2923184A patent/CA2923184A1/en not_active Abandoned
- 2014-09-02 SG SG11201601225RA patent/SG11201601225RA/en unknown
-
2016
- 2016-02-29 IL IL24434616A patent/IL244346B/en not_active IP Right Cessation
- 2016-03-04 CL CL2016000508A patent/CL2016000508A1/es unknown
-
2018
- 2018-01-18 CL CL2018000150A patent/CL2018000150A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016536333A5 (enExample) | ||
| RU2506257C2 (ru) | Замещенные пирролидин-2-карбоксамиды | |
| RU2011127232A (ru) | Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| RU2013133800A (ru) | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний | |
| JP2025016684A5 (enExample) | ||
| CA2487489A1 (en) | Mitotic kinesin inhibitors | |
| JP2019525941A5 (enExample) | ||
| AR128079A1 (es) | Composición farmacéutica que comprende un compuesto de quinazolina | |
| RU2010106974A (ru) | Ариловые эфиры пирролидина в качестве антагонистов рецепторов nk3 | |
| JPWO2021087025A5 (enExample) | ||
| JP2013510876A5 (enExample) | ||
| JP2013512899A5 (enExample) | ||
| RU2014108140A (ru) | Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ | |
| JP2012520238A5 (enExample) | ||
| JP2014510708A5 (enExample) | ||
| RU2013157374A (ru) | Производное индазола и пирролопиридина и его фармацевтическое применение | |
| RU2008126391A (ru) | Производные 1,5-замещенного индол-2-иламида | |
| JP2014531436A5 (enExample) | ||
| JPWO2020165833A5 (enExample) | ||
| JP2016514709A5 (enExample) | ||
| JP2009504664A5 (enExample) | ||
| US9226916B2 (en) | Pyrrolidine derivatives | |
| JP2014133739A5 (enExample) | ||
| RU2008108939A (ru) | Замещенные имидазолы, фармацевтическая композиция, способ лечения заболевания, связанного по крайней мере с активностью ksp, способ ингибирования ksp, лекарственное средство для лечения рака | |
| JP2018515489A5 (enExample) |